HEADER TRANSFERASE 13-MAY-09 2WIH TITLE STRUCTURE OF CDK2-CYCLIN A WITH PHA-848125 COMPND MOL_ID: 1; COMPND 2 MOLECULE: CELL DIVISION PROTEIN KINASE 2; COMPND 3 CHAIN: A, C; COMPND 4 SYNONYM: P33 PROTEIN KINASE; COMPND 5 EC: 2.7.1.37; COMPND 6 ENGINEERED: YES; COMPND 7 MOL_ID: 2; COMPND 8 MOLECULE: CYCLIN-A2; COMPND 9 CHAIN: B, D; COMPND 10 FRAGMENT: C-TERMINAL PORTION, RESIDUES 173-432; COMPND 11 SYNONYM: CYCLIN A, CYCLIN A2; COMPND 12 ENGINEERED: YES SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 3 ORGANISM_COMMON: HUMAN; SOURCE 4 ORGANISM_TAXID: 9606; SOURCE 5 EXPRESSION_SYSTEM: TRICHOPLUSIA NI; SOURCE 6 EXPRESSION_SYSTEM_TAXID: 7111; SOURCE 7 EXPRESSION_SYSTEM_CELL_LINE: HIGH FIVE; SOURCE 8 EXPRESSION_SYSTEM_VECTOR_TYPE: BACULOVIRUS; SOURCE 9 MOL_ID: 2; SOURCE 10 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 11 ORGANISM_COMMON: HUMAN; SOURCE 12 ORGANISM_TAXID: 9606; SOURCE 13 EXPRESSION_SYSTEM: ESCHERICHIA COLI BL21; SOURCE 14 EXPRESSION_SYSTEM_TAXID: 511693; SOURCE 15 EXPRESSION_SYSTEM_PLASMID: PGEX6P KEYWDS CELL CYCLE, ATP-BINDING, TRANSFERASE, POLYMORPHISM, PHOSPHORYLATION, KEYWDS 2 NUCLEOTIDE-BINDING, CELL DIVISION, SERINE/THREONINE-PROTEIN 2 KEYWDS 3 KINASE, PHOSPHOPROTEIN, SERINE/THREONINE-PROTEIN KINASE, MITOSIS EXPDTA X-RAY DIFFRACTION AUTHOR M.G.BRASCA,N.AMBOLDI,D.BALLINARI,A.D.CAMERON,E.CASALE,G.CERVI, AUTHOR 2 M.COLOMBO,F.COLOTTA,V.CROCI,R.DALESSIO,F.FIORENTINI,A.ISACCHI, AUTHOR 3 C.MERCURIO,W.MORETTI,A.PANZERI,W.PASTORI,P.PEVARELLO,F.QUARTIERI, AUTHOR 4 F.ROLETTO,G.TRAQUANDI,P.VIANELLO,A.VULPETTI,M.CIOMEI REVDAT 4 08-MAY-24 2WIH 1 REMARK REVDAT 3 03-APR-19 2WIH 1 SOURCE REVDAT 2 20-APR-11 2WIH 1 KEYWDS JRNL REMARK DBREF REVDAT 2 2 1 SEQADV FORMUL REVDAT 1 28-JUL-09 2WIH 0 JRNL AUTH M.G.BRASCA,N.AMBOLDI,D.BALLINARI,A.D.CAMERON,E.CASALE, JRNL AUTH 2 G.CERVI,M.COLOMBO,F.COLOTTA,V.CROCI,R.DALESSIO,F.FIORENTINI, JRNL AUTH 3 A.ISACCHI,C.MERCURIO,W.MORETTI,A.PANZERI,W.PASTORI, JRNL AUTH 4 P.PEVARELLO,F.QUARTIERI,F.ROLETTO,G.TRAQUANDI,P.VIANELLO, JRNL AUTH 5 A.VULPETTI,M.CIOMEI JRNL TITL IDENTIFICATION OF JRNL TITL 2 N,1,4,4-TETRAMETHYL-8-{[4-(4-METHYLPIPERAZIN-1-YL) JRNL TITL 3 PHENYL]AMINO}-4,5-DIHYDRO-1H-PYRAZOLO[4, JRNL TITL 4 3-H]QUINAZOLINE-3-CARBOXAMIDE (PHA-848125), A POTENT, ORALLY JRNL TITL 5 AVAILABLE CYCLIN DEPENDENT KINASE INHIBITOR. JRNL REF J.MED.CHEM. V. 52 5152 2009 JRNL REFN ISSN 0022-2623 JRNL PMID 19603809 JRNL DOI 10.1021/JM9006559 REMARK 2 REMARK 2 RESOLUTION. 2.50 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : CNX REMARK 3 AUTHORS : BRUNGER,ADAMS,CLORE,DELANO,GROS,GROSSE- REMARK 3 : KUNSTLEVE,JIANG,KUSZEWSKI,NILGES,PANNU, REMARK 3 : READ,RICE,SIMONSON,WARREN,ACCELRYS REMARK 3 : SOFTWARE INC.(BADGER,BERARD,KUMAR,SZALMA, REMARK 3 : YIP,DZAKULA) REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 2.50 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 29.96 REMARK 3 DATA CUTOFF (SIGMA(F)) : 0.000 REMARK 3 DATA CUTOFF HIGH (ABS(F)) : 4212802.710 REMARK 3 DATA CUTOFF LOW (ABS(F)) : 0.0000 REMARK 3 COMPLETENESS (WORKING+TEST) (%) : 99.6 REMARK 3 NUMBER OF REFLECTIONS : 72889 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 CROSS-VALIDATION METHOD : THROUGHOUT REMARK 3 FREE R VALUE TEST SET SELECTION : RANDOM REMARK 3 R VALUE (WORKING + TEST SET) : 0.215 REMARK 3 R VALUE (WORKING SET) : 0.213 REMARK 3 FREE R VALUE : 0.250 REMARK 3 FREE R VALUE TEST SET SIZE (%) : 5.100 REMARK 3 FREE R VALUE TEST SET COUNT : 3685 REMARK 3 ESTIMATED ERROR OF FREE R VALUE : 0.004 REMARK 3 REMARK 3 FIT/AGREEMENT OF MODEL WITH ALL DATA. REMARK 3 R VALUE (WORKING + TEST SET, NO CUTOFF) : 0.2350 REMARK 3 R VALUE (WORKING SET, NO CUTOFF) : 0.2330 REMARK 3 FREE R VALUE (NO CUTOFF) : 0.264 REMARK 3 FREE R VALUE TEST SET SIZE (%, NO CUTOFF) : 5.100 REMARK 3 FREE R VALUE TEST SET COUNT (NO CUTOFF) : 3685 REMARK 3 ESTIMATED ERROR OF FREE R VALUE (NO CUTOFF) : 0.0040 REMARK 3 TOTAL NUMBER OF REFLECTIONS (NO CUTOFF) : 72889 REMARK 3 REMARK 3 FIT IN THE HIGHEST RESOLUTION BIN. REMARK 3 TOTAL NUMBER OF BINS USED : 6 REMARK 3 BIN RESOLUTION RANGE HIGH (A) : 2.50 REMARK 3 BIN RESOLUTION RANGE LOW (A) : 2.66 REMARK 3 BIN COMPLETENESS (WORKING+TEST) (%) : 99.90 REMARK 3 REFLECTIONS IN BIN (WORKING SET) : 11358 REMARK 3 BIN R VALUE (WORKING SET) : 0.2930 REMARK 3 BIN FREE R VALUE : 0.3350 REMARK 3 BIN FREE R VALUE TEST SET SIZE (%) : 5.10 REMARK 3 BIN FREE R VALUE TEST SET COUNT : 611 REMARK 3 ESTIMATED ERROR OF BIN FREE R VALUE : 0.014 REMARK 3 REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT. REMARK 3 PROTEIN ATOMS : 8976 REMARK 3 NUCLEIC ACID ATOMS : 0 REMARK 3 HETEROGEN ATOMS : 73 REMARK 3 SOLVENT ATOMS : 214 REMARK 3 REMARK 3 B VALUES. REMARK 3 FROM WILSON PLOT (A**2) : 45.60 REMARK 3 MEAN B VALUE (OVERALL, A**2) : 48.50 REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : 5.95000 REMARK 3 B22 (A**2) : 5.95000 REMARK 3 B33 (A**2) : -11.91000 REMARK 3 B12 (A**2) : 7.54000 REMARK 3 B13 (A**2) : 0.00000 REMARK 3 B23 (A**2) : 0.00000 REMARK 3 REMARK 3 ESTIMATED COORDINATE ERROR. REMARK 3 ESD FROM LUZZATI PLOT (A) : 0.32 REMARK 3 ESD FROM SIGMAA (A) : 0.32 REMARK 3 LOW RESOLUTION CUTOFF (A) : 5.00 REMARK 3 REMARK 3 CROSS-VALIDATED ESTIMATED COORDINATE ERROR. REMARK 3 ESD FROM C-V LUZZATI PLOT (A) : 0.38 REMARK 3 ESD FROM C-V SIGMAA (A) : 0.38 REMARK 3 REMARK 3 RMS DEVIATIONS FROM IDEAL VALUES. REMARK 3 BOND LENGTHS (A) : 0.006 REMARK 3 BOND ANGLES (DEGREES) : 0.900 REMARK 3 DIHEDRAL ANGLES (DEGREES) : 21.00 REMARK 3 IMPROPER ANGLES (DEGREES) : 0.690 REMARK 3 REMARK 3 ISOTROPIC THERMAL MODEL : RESTRAINED REMARK 3 REMARK 3 ISOTROPIC THERMAL FACTOR RESTRAINTS. RMS SIGMA REMARK 3 MAIN-CHAIN BOND (A**2) : 1.470 ; 1.500 REMARK 3 MAIN-CHAIN ANGLE (A**2) : 2.500 ; 2.000 REMARK 3 SIDE-CHAIN BOND (A**2) : 2.190 ; 2.000 REMARK 3 SIDE-CHAIN ANGLE (A**2) : 3.350 ; 2.500 REMARK 3 REMARK 3 BULK SOLVENT MODELING. REMARK 3 METHOD USED : FLAT MODEL REMARK 3 KSOL : 0.32 REMARK 3 BSOL : 24.46 REMARK 3 REMARK 3 NCS MODEL : NULL REMARK 3 REMARK 3 NCS RESTRAINTS. RMS SIGMA/WEIGHT REMARK 3 GROUP 1 POSITIONAL (A) : NULL ; NULL REMARK 3 GROUP 1 B-FACTOR (A**2) : NULL ; NULL REMARK 3 REMARK 3 PARAMETER FILE 1 : PROTEIN_REP.PARAM REMARK 3 PARAMETER FILE 2 : WATER_REP.PARAM REMARK 3 PARAMETER FILE 3 : 125.PAR REMARK 3 PARAMETER FILE 4 : NULL REMARK 3 TOPOLOGY FILE 1 : PROTEIN.TOP REMARK 3 TOPOLOGY FILE 2 : WATER.TOP REMARK 3 TOPOLOGY FILE 3 : 125.TOP REMARK 3 TOPOLOGY FILE 4 : NULL REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: THERE IS A FEATURE IN THE ELECTRON REMARK 3 DENSITY MAP ATTACHED TO ASP 28 OF BOTH CDK2 MOLECULES THAT COULD REMARK 3 NOT BE ASSIGNED TO ANY MOLECULE IN THE CRYSTALLISATION MIXTURE. REMARK 3 THIS HAS BEEN MODELLED BY WATER MOLECULES. REMARK 4 REMARK 4 2WIH COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY PDBE ON 13-MAY-09. REMARK 100 THE DEPOSITION ID IS D_1290039796. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 28-APR-08 REMARK 200 TEMPERATURE (KELVIN) : 100 REMARK 200 PH : NULL REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : Y REMARK 200 RADIATION SOURCE : ESRF REMARK 200 BEAMLINE : ID14-4 REMARK 200 X-RAY GENERATOR MODEL : NULL REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 0.97 REMARK 200 MONOCHROMATOR : NULL REMARK 200 OPTICS : NULL REMARK 200 REMARK 200 DETECTOR TYPE : CCD REMARK 200 DETECTOR MANUFACTURER : ADSC CCD REMARK 200 INTENSITY-INTEGRATION SOFTWARE : DENZO REMARK 200 DATA SCALING SOFTWARE : SCALEPACK REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 72932 REMARK 200 RESOLUTION RANGE HIGH (A) : 2.500 REMARK 200 RESOLUTION RANGE LOW (A) : 30.000 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : 0.000 REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 99.7 REMARK 200 DATA REDUNDANCY : 7.000 REMARK 200 R MERGE (I) : 0.09000 REMARK 200 R SYM (I) : NULL REMARK 200 FOR THE DATA SET : 16.1000 REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 2.50 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 2.60 REMARK 200 COMPLETENESS FOR SHELL (%) : 100.0 REMARK 200 DATA REDUNDANCY IN SHELL : 0.00 REMARK 200 R MERGE FOR SHELL (I) : 0.57000 REMARK 200 R SYM FOR SHELL (I) : NULL REMARK 200 FOR SHELL : 3.700 REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: OTHER REMARK 200 SOFTWARE USED: NULL REMARK 200 STARTING MODEL: NONE REMARK 200 REMARK 200 REMARK: NONE REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 64.00 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 4.00 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: 20% AMMONIUM SULPHATE, 1M KCL, 40MM REMARK 280 HEPES PH 7 REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: P 62 2 2 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -Y,X-Y,Z+2/3 REMARK 290 3555 -X+Y,-X,Z+1/3 REMARK 290 4555 -X,-Y,Z REMARK 290 5555 Y,-X+Y,Z+2/3 REMARK 290 6555 X-Y,X,Z+1/3 REMARK 290 7555 Y,X,-Z+2/3 REMARK 290 8555 X-Y,-Y,-Z REMARK 290 9555 -X,-X+Y,-Z+1/3 REMARK 290 10555 -Y,-X,-Z+2/3 REMARK 290 11555 -X+Y,Y,-Z REMARK 290 12555 X,X-Y,-Z+1/3 REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -0.500000 -0.866025 0.000000 0.00000 REMARK 290 SMTRY2 2 0.866025 -0.500000 0.000000 0.00000 REMARK 290 SMTRY3 2 0.000000 0.000000 1.000000 142.37333 REMARK 290 SMTRY1 3 -0.500000 0.866025 0.000000 0.00000 REMARK 290 SMTRY2 3 -0.866025 -0.500000 0.000000 0.00000 REMARK 290 SMTRY3 3 0.000000 0.000000 1.000000 71.18667 REMARK 290 SMTRY1 4 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 4 0.000000 -1.000000 0.000000 0.00000 REMARK 290 SMTRY3 4 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 5 0.500000 0.866025 0.000000 0.00000 REMARK 290 SMTRY2 5 -0.866025 0.500000 0.000000 0.00000 REMARK 290 SMTRY3 5 0.000000 0.000000 1.000000 142.37333 REMARK 290 SMTRY1 6 0.500000 -0.866025 0.000000 0.00000 REMARK 290 SMTRY2 6 0.866025 0.500000 0.000000 0.00000 REMARK 290 SMTRY3 6 0.000000 0.000000 1.000000 71.18667 REMARK 290 SMTRY1 7 -0.500000 0.866025 0.000000 0.00000 REMARK 290 SMTRY2 7 0.866025 0.500000 0.000000 0.00000 REMARK 290 SMTRY3 7 0.000000 0.000000 -1.000000 142.37333 REMARK 290 SMTRY1 8 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 8 0.000000 -1.000000 0.000000 0.00000 REMARK 290 SMTRY3 8 0.000000 0.000000 -1.000000 0.00000 REMARK 290 SMTRY1 9 -0.500000 -0.866025 0.000000 0.00000 REMARK 290 SMTRY2 9 -0.866025 0.500000 0.000000 0.00000 REMARK 290 SMTRY3 9 0.000000 0.000000 -1.000000 71.18667 REMARK 290 SMTRY1 10 0.500000 -0.866025 0.000000 0.00000 REMARK 290 SMTRY2 10 -0.866025 -0.500000 0.000000 0.00000 REMARK 290 SMTRY3 10 0.000000 0.000000 -1.000000 142.37333 REMARK 290 SMTRY1 11 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 11 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 11 0.000000 0.000000 -1.000000 0.00000 REMARK 290 SMTRY1 12 0.500000 0.866025 0.000000 0.00000 REMARK 290 SMTRY2 12 0.866025 -0.500000 0.000000 0.00000 REMARK 290 SMTRY3 12 0.000000 0.000000 -1.000000 71.18667 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1, 2 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: DIMERIC REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: DIMERIC REMARK 350 SOFTWARE USED: PISA REMARK 350 TOTAL BURIED SURFACE AREA: 2920 ANGSTROM**2 REMARK 350 SURFACE AREA OF THE COMPLEX: 23500 ANGSTROM**2 REMARK 350 CHANGE IN SOLVENT FREE ENERGY: -10.5 KCAL/MOL REMARK 350 APPLY THE FOLLOWING TO CHAINS: A, B REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 350 REMARK 350 BIOMOLECULE: 2 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: DIMERIC REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: DIMERIC REMARK 350 SOFTWARE USED: PISA REMARK 350 TOTAL BURIED SURFACE AREA: 3230 ANGSTROM**2 REMARK 350 SURFACE AREA OF THE COMPLEX: 23010 ANGSTROM**2 REMARK 350 CHANGE IN SOLVENT FREE ENERGY: -22.3 KCAL/MOL REMARK 350 APPLY THE FOLLOWING TO CHAINS: C, D REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 465 REMARK 465 MISSING RESIDUES REMARK 465 THE FOLLOWING RESIDUES WERE NOT LOCATED IN THE REMARK 465 EXPERIMENT. (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 465 IDENTIFIER; SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.) REMARK 465 REMARK 465 M RES C SSSEQI REMARK 465 GLY A -4 REMARK 465 GLU A 299 REMARK 465 ARG A 300 REMARK 465 PRO A 301 REMARK 465 HIS A 302 REMARK 465 ARG A 303 REMARK 465 ASP A 304 REMARK 465 GLY B 168 REMARK 465 PRO B 169 REMARK 465 LEU B 170 REMARK 465 GLY B 171 REMARK 465 SER B 172 REMARK 465 ASN B 173 REMARK 465 GLU B 174 REMARK 465 VAL B 175 REMARK 465 GLY C -4 REMARK 465 PRO C -3 REMARK 465 LEU C -2 REMARK 465 VAL C -1 REMARK 465 GLU C 299 REMARK 465 ARG C 300 REMARK 465 PRO C 301 REMARK 465 HIS C 302 REMARK 465 ARG C 303 REMARK 465 ASP C 304 REMARK 465 GLY D 168 REMARK 465 PRO D 169 REMARK 465 LEU D 170 REMARK 465 GLY D 171 REMARK 465 SER D 172 REMARK 465 ASN D 173 REMARK 465 GLU D 174 REMARK 465 VAL D 175 REMARK 465 GLN D 323 REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 VAL A 7 -61.80 -96.84 REMARK 500 GLU A 40 -30.91 -135.86 REMARK 500 ARG A 126 -0.51 79.63 REMARK 500 ASP A 145 78.82 62.06 REMARK 500 CYS B 193 32.36 -81.39 REMARK 500 PHE B 304 12.91 59.65 REMARK 500 TRP B 372 109.44 -34.17 REMARK 500 GLU C 42 -50.43 -132.77 REMARK 500 HIS C 121 31.83 -98.35 REMARK 500 ARG C 126 -5.97 76.18 REMARK 500 ASP C 145 87.79 64.60 REMARK 500 GLU C 162 152.64 -45.20 REMARK 500 VAL C 163 -70.30 -125.83 REMARK 500 ARG C 297 92.10 -69.23 REMARK 500 CYS D 193 37.64 -85.83 REMARK 500 PHE D 304 14.70 57.62 REMARK 500 LEU D 320 10.15 -68.61 REMARK 500 TRP D 372 106.27 -32.22 REMARK 500 REMARK 500 REMARK: NULL REMARK 800 REMARK 800 SITE REMARK 800 SITE_IDENTIFIER: AC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE SO4 D 1433 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC2 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE P48 C 1299 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC3 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE P48 A 1299 REMARK 900 REMARK 900 RELATED ENTRIES REMARK 900 RELATED ID: 1H08 RELATED DB: PDB REMARK 900 CDK2 IN COMPLEX WITH A DISUBSTITUTED 2, 4 -BIS ANILINO PYRIMIDINE REMARK 900 CDK4 INHIBITOR REMARK 900 RELATED ID: 1PYE RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF CDK2 WITH INHIBITOR REMARK 900 RELATED ID: 2VTH RELATED DB: PDB REMARK 900 IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(2,6 -DICHLOROBENZOYLAMINO)- REMARK 900 1H-PYRAZOLE-3- CARBOXAMIDE (AT7519), A NOVEL CYCLIN DEPENDENT REMARK 900 KINASE INHIBITOR USING FRAGMENT-BASED X-RAY CRYSTALLOGRAPHY AND REMARK 900 STRUCTURE BASED DRUG DESIGN. REMARK 900 RELATED ID: 2B53 RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH DIN-234325 REMARK 900 RELATED ID: 1V1K RELATED DB: PDB REMARK 900 CDK2 IN COMPLEX WITH A DISUBSTITUTED 4, 6 -BIS ANILINO PYRIMIDINE REMARK 900 CDK4 INHIBITOR REMARK 900 RELATED ID: 1KE7 RELATED DB: PDB REMARK 900 CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH 3-{[(2,2-DIOXIDO-1, REMARK 900 3-DIHYDRO-2- BENZOTHIEN-5-YL)AMINO]METHYLENE}-5-(1,3- OXAZOL-5-YL)- REMARK 900 1,3-DIHYDRO-2H-INDOL-2-ONE REMARK 900 RELATED ID: 1OKV RELATED DB: PDB REMARK 900 CYCLIN A BINDING GROOVE INHIBITOR H-ARG- ARG-LEU-ILE-PHE-NH2 REMARK 900 RELATED ID: 1H25 RELATED DB: PDB REMARK 900 CDK2/CYCLINA IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM REMARK 900 E2F REMARK 900 RELATED ID: 1PXK RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THEINHIBITOR N-[4-(2, REMARK 900 4-DIMETHYL- THIAZOL-5-YL)PYRIMIDIN-2-YL]-N'- HYDROXYIMINOFORMAMIDE REMARK 900 RELATED ID: 2BHH RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT PROTEIN KINASE 2 IN COMPLEX WITH THE REMARK 900 INHIBITOR 4- HYDROXYPIPERINDINESULFONYL-INDIRUBINE REMARK 900 RELATED ID: 2UUE RELATED DB: PDB REMARK 900 REPLACE: A STRATEGY FOR ITERATIVE DESIGN OF CYCLIN BINDING GROOVE REMARK 900 INHIBITORS REMARK 900 RELATED ID: 2VTA RELATED DB: PDB REMARK 900 IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(2,6 -DICHLOROBENZOYLAMINO)- REMARK 900 1H-PYRAZOLE-3- CARBOXAMIDE (AT7519), A NOVEL CYCLIN DEPENDENT REMARK 900 KINASE INHIBITOR USING FRAGMENT-BASED X-RAY CRYSTALLOGRAPHY AND REMARK 900 STRUCTURE BASED DRUG DESIGN. REMARK 900 RELATED ID: 1GZ8 RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR 2- REMARK 900 AMINO-6-(3'-METHYL- 2'-OXO)BUTOXYPURINE REMARK 900 RELATED ID: 1E1V RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR NU2058 REMARK 900 RELATED ID: 1OL2 RELATED DB: PDB REMARK 900 CYCLIN A BINDING GROOVE INHIBITOR H-ARG- ARG-LEU-ASN-(P-F-PHE)-NH2 REMARK 900 RELATED ID: 1H27 RELATED DB: PDB REMARK 900 CDK2/CYCLINA IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM REMARK 900 P27 REMARK 900 RELATED ID: 1JSV RELATED DB: PDB REMARK 900 THE STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 (CDK2) INCOMPLEX WITH 4- REMARK 900 [(6-AMINO-4- PYRIMIDINYL)AMINO]BENZENESULFONAMIDE REMARK 900 RELATED ID: 2B52 RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH DPH-042562 REMARK 900 RELATED ID: 2WHA RELATED DB: PDB REMARK 900 TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2, CYCLIN A REMARK 900 THROUGH STRUCTURE GUIDED DESIGN REMARK 900 RELATED ID: 1KE5 RELATED DB: PDB REMARK 900 CDK2 COMPLEXED WITH N-METHYL-4-{[(2-OXO- 1,2-DIHYDRO-3H-INDOL-3- REMARK 900 YLIDENE)METHYL] AMINO}BENZENESULFONAMIDE REMARK 900 RELATED ID: 1FIN RELATED DB: PDB REMARK 900 CYCLIN A - CYCLIN-DEPENDENT KINASE 2 COMPLEX REMARK 900 RELATED ID: 2C5O RELATED DB: PDB REMARK 900 DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 REMARK 900 PROVIDES INSIGHTS FOR DRUG DESIGN REMARK 900 RELATED ID: 2C68 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE REMARK 900 TRIAZOLOPYRIMIDINE INHIBITOR REMARK 900 RELATED ID: 2VTT RELATED DB: PDB REMARK 900 IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(2,6 -DICHLOROBENZOYLAMINO)- REMARK 900 1H-PYRAZOLE-3- CARBOXAMIDE (AT7519), A NOVEL CYCLIN DEPENDENT REMARK 900 KINASE INHIBITOR USING FRAGMENT-BASED X- RAY CRYSTALLOGRAPHY AND REMARK 900 STRUCTURE BASED DRUG DESIGN REMARK 900 RELATED ID: 1P2A RELATED DB: PDB REMARK 900 THE STRUCTURE OF CYCLIN DEPENDENT KINASE 2 (CKD2) WITH REMARK 900 ATRISUBSTITUTED NAPHTHOSTYRIL INHIBITOR REMARK 900 RELATED ID: 2VTQ RELATED DB: PDB REMARK 900 IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(2,6 -DICHLOROBENZOYLAMINO)- REMARK 900 1H-PYRAZOLE-3- CARBOXAMIDE (AT7519), A NOVEL CYCLIN DEPENDENT REMARK 900 KINASE INHIBITOR USING FRAGMENT-BASED X-RAY CRYSTALLOGRAPHY AND REMARK 900 STRUCTURE BASED DRUG DESIGN. REMARK 900 RELATED ID: 2C4G RELATED DB: PDB REMARK 900 STRUCTURE OF CDK2-CYCLIN A WITH PHA-533514 REMARK 900 RELATED ID: 1H1Q RELATED DB: PDB REMARK 900 STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/ CYCLIN A COMPLEXED WITH THE REMARK 900 INHIBITOR NU6094 REMARK 900 RELATED ID: 1W0X RELATED DB: PDB REMARK 900 CRYSTALS STRUCTURE OF HUMAN CDK2 IN COMPLEX WITH THE INHIBITOR REMARK 900 OLOMOUCINE. REMARK 900 RELATED ID: 2W05 RELATED DB: PDB REMARK 900 STRUCTURE OF CDK2 IN COMPLEX WITH AN IMIDAZOLYL PYRIMIDINE, REMARK 900 COMPOUND 5B REMARK 900 RELATED ID: 1PXO RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THEINHIBITOR [4-(2- REMARK 900 AMINO-4-METHYL- THIAZOL-5-YL)-PYRIMIDIN-2-YL]-(3-NITRO- PHENYL)- REMARK 900 AMINE REMARK 900 RELATED ID: 1KE9 RELATED DB: PDB REMARK 900 CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH 3-{[4-({ REMARK 900 [AMINO(IMINO)METHYL] AMINOSULFONYL)ANILINO]METHYLENE}-2-OXO-2,3- REMARK 900 DIHYDRO-1H-INDOLE REMARK 900 RELATED ID: 1HCK RELATED DB: PDB REMARK 900 HUMAN CYCLIN-DEPENDENT KINASE 2 REMARK 900 RELATED ID: 2A0C RELATED DB: PDB REMARK 900 HUMAN CDK2 IN COMPLEX WITH OLOMOUCINE II, A NOVEL 2,6,9- REMARK 900 TRISUBSTITUTED PURINE CYCLIN -DEPENDENT KINASE INHIBITOR REMARK 900 RELATED ID: 1JSU RELATED DB: PDB REMARK 900 P27(KIP1)/CYCLIN A/CDK2 COMPLEX REMARK 900 RELATED ID: 1PXN RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THEINHIBITOR 4-[4-(4- REMARK 900 METHYL-2- METHYLAMINO-THIAZOL-5-YL)-PYRIMIDIN-2- YLAMINO]-PHENOL REMARK 900 RELATED ID: 2UZE RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE REMARK 900 INHIBITOR REMARK 900 RELATED ID: 2VTM RELATED DB: PDB REMARK 900 IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(2,6 -DICHLOROBENZOYLAMINO)- REMARK 900 1H-PYRAZOLE-3- CARBOXAMIDE (AT7519), A NOVEL CYCLIN DEPENDENT REMARK 900 KINASE INHIBITOR USING FRAGMENT-BASED X-RAY CRYSTALLOGRAPHY AND REMARK 900 STRUCTURE BASED DRUG DESIGN. REMARK 900 RELATED ID: 2V0D RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE REMARK 900 INHIBITOR REMARK 900 RELATED ID: 1OIQ RELATED DB: PDB REMARK 900 IMIDAZOPYRIDINES: A POTENT AND SELECTIVE CLASS OF CYCLIN-DEPENDENT REMARK 900 KINASE INHIBITORS IDENTIFIED THROUGH STRUCTURE-BASED HYBRIDISATION REMARK 900 RELATED ID: 1H1R RELATED DB: PDB REMARK 900 STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/ CYCLIN A COMPLEXED WITH THE REMARK 900 INHIBITOR NU6086 REMARK 900 RELATED ID: 2IW8 RELATED DB: PDB REMARK 900 STRUCTURE OF HUMAN THR160-PHOSPHO CDK2- CYCLIN A F82H-L83V-H84D REMARK 900 MUTANT WITH AN O6-CYCLOHEXYLMETHYLGUANINE INHIBITOR REMARK 900 RELATED ID: 1PW2 RELATED DB: PDB REMARK 900 APO STRUCTURE OF HUMAN CYCLIN-DEPENDENT KINASE 2 REMARK 900 RELATED ID: 1HCL RELATED DB: PDB REMARK 900 HUMAN CYCLIN-DEPENDENT KINASE 2 REMARK 900 RELATED ID: 1GIH RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE CDK4INHIBITOR REMARK 900 RELATED ID: 2WHB RELATED DB: PDB REMARK 900 TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2, CYCLIN A REMARK 900 THROUGH STRUCTURE GUIDED DESIGN REMARK 900 RELATED ID: 2W06 RELATED DB: PDB REMARK 900 STRUCTURE OF CDK2 IN COMPLEX WITH AN IMIDAZOLYL PYRIMIDINE, REMARK 900 COMPOUND 5C REMARK 900 RELATED ID: 2VTN RELATED DB: PDB REMARK 900 IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(2,6 -DICHLOROBENZOYLAMINO)- REMARK 900 1H-PYRAZOLE-3- CARBOXAMIDE (AT7519), A NOVEL CYCLIN DEPENDENT REMARK 900 KINASE INHIBITOR USING FRAGMENT-BASED X-RAY CRYSTALLOGRAPHY AND REMARK 900 STRUCTURE BASED DRUG DESIGN. REMARK 900 RELATED ID: 1JST RELATED DB: PDB REMARK 900 PHOSPHORYLATED CYCLIN-DEPENDENT KINASE-2 BOUND TO CYCLIN A REMARK 900 RELATED ID: 1OIU RELATED DB: PDB REMARK 900 STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/ CYCLIN A COMPLEXED WITH A 6- REMARK 900 CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR REMARK 900 RELATED ID: 1PXM RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THEINHIBITOR 3-[4-(2, REMARK 900 4-DIMETHYL- THIAZOL-5-YL)-PYRIMIDIN-2-YLAMINO]-PHENOL REMARK 900 RELATED ID: 1B38 RELATED DB: PDB REMARK 900 HUMAN CYCLIN-DEPENDENT KINASE 2 REMARK 900 RELATED ID: 1FQ1 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF KINASE ASSOCIATED PHOSPHATASE (KAP) INCOMPLEX REMARK 900 WITH PHOSPHO-CDK2 REMARK 900 RELATED ID: 1VYW RELATED DB: PDB REMARK 900 STRUCTURE OF CDK2/CYCLIN A WITH PNU-292137 REMARK 900 RELATED ID: 1H1P RELATED DB: PDB REMARK 900 STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/ CYCLIN A COMPLEXED WITH THE REMARK 900 INHIBITOR NU2058 REMARK 900 RELATED ID: 2C69 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE REMARK 900 TRIAZOLOPYRIMIDINE INHIBITOR REMARK 900 RELATED ID: 1URC RELATED DB: PDB REMARK 900 CYCLIN A BINDING GROOVE INHIBITOR H-ARG- ARG-LEU-ASN-(P-F-PHE)-NH2 REMARK 900 RELATED ID: 1PXI RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THEINHIBITOR 4-(2,5- REMARK 900 DICHLORO-THIOPHEN- 3-YL)-PYRIMIDIN-2-YLAMINE REMARK 900 RELATED ID: 2C6I RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE REMARK 900 TRIAZOLOPYRIMIDINE INHIBITOR REMARK 900 RELATED ID: 1YKR RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF CDK2 WITH AN AMINOIMIDAZO PYRIDINEINHIBITOR REMARK 900 RELATED ID: 2W17 RELATED DB: PDB REMARK 900 CDK2 IN COMPLEX WITH THE IMIDAZOLE PYRIMIDINE AMIDE, COMPOUND (S)-8B REMARK 900 RELATED ID: 2C5Y RELATED DB: PDB REMARK 900 DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 REMARK 900 PROVIDES INSIGHTS FOR DRUG DESIGN REMARK 900 RELATED ID: 2UZD RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE REMARK 900 INHIBITOR REMARK 900 RELATED ID: 2C6K RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE REMARK 900 TRIAZOLOPYRIMIDINE INHIBITOR REMARK 900 RELATED ID: 1WCC RELATED DB: PDB REMARK 900 SCREENING FOR FRAGMENT BINDING BY X-RAY CRYSTALLOGRAPHY REMARK 900 RELATED ID: 2J9M RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH MACROCYCLIC REMARK 900 AMINOPYRIMIDINE REMARK 900 RELATED ID: 1VYZ RELATED DB: PDB REMARK 900 STRUCTURE OF CDK2 COMPLEXED WITH PNU-181227 REMARK 900 RELATED ID: 2VTI RELATED DB: PDB REMARK 900 IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(2,6 -DICHLOROBENZOYLAMINO)- REMARK 900 1H-PYRAZOLE-3- CARBOXAMIDE (AT7519), A NOVEL CYCLIN DEPENDENT REMARK 900 KINASE INHIBITOR USING FRAGMENT-BASED X-RAY CRYSTALLOGRAPHY AND REMARK 900 STRUCTURE BASED DRUG DESIGN. REMARK 900 RELATED ID: 1JVP RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CDK2 (UNPHOSPHORYLATED) INCOMPLEX WITH REMARK 900 PKF049-365 REMARK 900 RELATED ID: 1W98 RELATED DB: PDB REMARK 900 THE STRUCTURAL BASIS OF CDK2 ACTIVATION BY CYCLIN E REMARK 900 RELATED ID: 1PKD RELATED DB: PDB REMARK 900 THE CRYSTAL STRUCTURE OF UCN-01 IN COMPLEX WITH PHOSPHO-CDK2/CYCLIN REMARK 900 A REMARK 900 RELATED ID: 1P5E RELATED DB: PDB REMARK 900 THE STRUCURE OF PHOSPHO-CDK2/CYCLIN A IN COMPLEX WITH THEINHIBITOR REMARK 900 4,5,6,7- TETRABROMOBENZOTRIAZOLE (TBS) REMARK 900 RELATED ID: 2VTS RELATED DB: PDB REMARK 900 IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(2,6 -DICHLOROBENZOYLAMINO)- REMARK 900 1H-PYRAZOLE-3- CARBOXAMIDE (AT7519), A NOVEL CYCLIN DEPENDENT REMARK 900 KINASE INHIBITOR USING FRAGMENT-BASED X-RAY CRYSTALLOGRAPHY AND REMARK 900 STRUCTURE BASED DRUG DESIGN. REMARK 900 RELATED ID: 2C5P RELATED DB: PDB REMARK 900 DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 REMARK 900 PROVIDES INSIGHTS FOR DRUG DESIGN REMARK 900 RELATED ID: 2UZN RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE REMARK 900 INHIBITOR REMARK 900 RELATED ID: 2B54 RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 (CKD2) COMPLEXED WITH DIN-232305 REMARK 900 RELATED ID: 1KE6 RELATED DB: PDB REMARK 900 CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH N-METHYL-{4-[2-(7- REMARK 900 OXO-6,7-DIHYDRO -8H-[1,3]THIAZOLO[5,4-E]INDOL-8- YLIDENE)HYDRAZINO] REMARK 900 PHENYL}METHANESULFONAMIDE REMARK 900 RELATED ID: 1PXJ RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THEINHIBITOR 4-(2,4- REMARK 900 DIMETHYL-THIAZOL- 5-YL)-PYRIMIDIN-2-YLAMINE REMARK 900 RELATED ID: 2UZL RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE REMARK 900 INHIBITOR REMARK 900 RELATED ID: 2CCI RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF PHOSPHO-CDK2 CYCLIN A IN COMPLEX WITH A REMARK 900 PEPTIDE CONTAINING BOTH THE SUBSTRATE AND RECRUITMENT SITES OF CDC6 REMARK 900 RELATED ID: 2BKZ RELATED DB: PDB REMARK 900 STRUCTURE OF CDK2-CYCLIN A WITH PHA-404611 REMARK 900 RELATED ID: 2G9X RELATED DB: PDB REMARK 900 STRUCTURE OF THR 160 PHOSPHORYLATED CDK2/ CYCLIN A INCOMPLEX WITH REMARK 900 THE INHIBITOR NU6271 REMARK 900 RELATED ID: 1Y91 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A PYRAZOLO[1,5-A] REMARK 900 PYRIMIDINE INHIBITOR REMARK 900 RELATED ID: 2IW6 RELATED DB: PDB REMARK 900 STRUCTURE OF HUMAN THR160-PHOSPHO CDK2-CYCLIN A COMPLEXED WITH A REMARK 900 BISANILINOPYRIMIDINE INHIBITOR REMARK 900 RELATED ID: 1GIJ RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE CDK4INHIBITOR REMARK 900 RELATED ID: 1R78 RELATED DB: PDB REMARK 900 CDK2 COMPLEX WITH A 4-ALKYNYL OXINDOLE INHIBITOR REMARK 900 RELATED ID: 1H0V RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT PROTEIN KINASE 2 IN COMPLEX WITH THE REMARK 900 INHIBITOR 2-AMINO-6-[(R )-PYRROLIDINO-5'-YL]METHOXYPURINE REMARK 900 RELATED ID: 2IW9 RELATED DB: PDB REMARK 900 STRUCTURE OF HUMAN THR160-PHOSPHO CDK2-CYCLIN A COMPLEXED WITH A REMARK 900 BISANILINOPYRIMIDINE INHIBITOR REMARK 900 RELATED ID: 1W8C RELATED DB: PDB REMARK 900 CO-CRYSTAL STRUCTURE OF 6-CYCLOHEXYLMETHOXY- 8-ISOPROPYL-9H-PURIN-2- REMARK 900 YLAMINE AND MONOMERIC CDK2 REMARK 900 RELATED ID: 1BUH RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF THE HUMAN CDK2 KINASE COMPLEX WITHCELL CYCLE- REMARK 900 REGULATORY PROTEIN CKSHS1 REMARK 900 RELATED ID: 2BPM RELATED DB: PDB REMARK 900 STRUCTURE OF CDK2-CYCLIN A WITH PHA-630529 REMARK 900 RELATED ID: 2BTS RELATED DB: PDB REMARK 900 STRUCTURE OF CDK2 COMPLEXED WITH PNU-230032 REMARK 900 RELATED ID: 1FVV RELATED DB: PDB REMARK 900 THE STRUCTURE OF CDK2/CYCLIN A IN COMPLEX WITH AN OXINDOLEINHIBITOR REMARK 900 RELATED ID: 1OKW RELATED DB: PDB REMARK 900 CYCLIN A BINDING GROOVE INHIBITOR AC-ARG- ARG-LEU-ASN-(M-CL-PHE)-NH2 REMARK 900 RELATED ID: 2VTP RELATED DB: PDB REMARK 900 IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(2,6 -DICHLOROBENZOYLAMINO)- REMARK 900 1H-PYRAZOLE-3- CARBOXAMIDE (AT7519), A NOVEL CYCLIN DEPENDENT REMARK 900 KINASE INHIBITOR USING FRAGMENT-BASED X-RAY CRYSTALLOGRAPHY AND REMARK 900 STRUCTURE BASED DRUG DESIGN. REMARK 900 RELATED ID: 2A4L RELATED DB: PDB REMARK 900 HUMAN CYCLIN-DEPENDENT KINASE 2 IN COMPLEX WITH ROSCOVITINE REMARK 900 RELATED ID: 2C6T RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE REMARK 900 TRIAZOLOPYRIMIDINE INHIBITOR REMARK 900 RELATED ID: 1FVT RELATED DB: PDB REMARK 900 THE STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 (CDK2) INCOMPLEX WITH AN REMARK 900 OXINDOLE INHIBITOR REMARK 900 RELATED ID: 1QMZ RELATED DB: PDB REMARK 900 PHOSPHORYLATED CDK2-CYCLYIN A-SUBSTRATE PEPTIDE COMPLEX REMARK 900 RELATED ID: 2W1H RELATED DB: PDB REMARK 900 FRAGMENT-BASED DISCOVERY OF THE PYRAZOL-4- YL UREA (AT9283), A REMARK 900 MULTI-TARGETED KINASE INHIBITOR WITH POTENT AURORA KINASE ACTIVITY REMARK 900 RELATED ID: 2VU3 RELATED DB: PDB REMARK 900 IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(2,6 -DICHLOROBENZOYLAMINO)- REMARK 900 1H-PYRAZOLE-3- CARBOXAMIDE (AT7519), A NOVEL CYCLIN DEPENDENT REMARK 900 KINASE INHIBITOR USING FRAGMENT-BASED X-RAY CRYSTALLOGRAPHY AND REMARK 900 STRUCTURE BASED DRUG DESIGN. REMARK 900 RELATED ID: 1OGU RELATED DB: PDB REMARK 900 STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/ CYCLIN A COMPLEXED WITH A 2- REMARK 900 ARYLAMINO-4- CYCLOHEXYLMETHYL-5-NITROSO-6-AMINOPYRIMIDINE INHIBITOR REMARK 900 RELATED ID: 2B55 RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 (CDK2) COMPLEXED WITHINDENOPYRAXOLE REMARK 900 DIN-101312 REMARK 900 RELATED ID: 1PF8 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CYCLIN-DEPENDENT KINASE 2COMPLEXED WITH REMARK 900 A NUCLEOSIDE INHIBITOR REMARK 900 RELATED ID: 1H1S RELATED DB: PDB REMARK 900 STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/ CYCLIN A COMPLEXED WITH THE REMARK 900 INHIBITOR NU6102 REMARK 900 RELATED ID: 2JGZ RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF PHOSPHO-CDK2 IN COMPLEX WITH CYCLIN B REMARK 900 RELATED ID: 2C5V RELATED DB: PDB REMARK 900 DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 REMARK 900 PROVIDES INSIGHTS FOR DRUG DESIGN REMARK 900 RELATED ID: 2BHE RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT PROTEIN KINASE 2 IN COMPLEX WITH THE REMARK 900 INHIBITOR 5-BROMO-INDIRUBINE REMARK 900 RELATED ID: 1URW RELATED DB: PDB REMARK 900 CDK2 IN COMPLEX WITH AN IMIDAZO[1,2-B] PYRIDAZINE REMARK 900 RELATED ID: 1OIY RELATED DB: PDB REMARK 900 STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/ CYCLIN A COMPLEXED WITH A 6- REMARK 900 CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR REMARK 900 RELATED ID: 2C6L RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE REMARK 900 TRIAZOLOPYRIMIDINE INHIBITOR REMARK 900 RELATED ID: 2C6O RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE REMARK 900 TRIAZOLOPYRIMIDINE INHIBITOR REMARK 900 RELATED ID: 1F5Q RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF MURINE GAMMA HERPESVIRUS CYCLIN COMPLEXED TO REMARK 900 HUMAN CYCLIN DEPENDANT KINASE 2 REMARK 900 RELATED ID: 2VTL RELATED DB: PDB REMARK 900 IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(2,6 -DICHLOROBENZOYLAMINO)- REMARK 900 1H-PYRAZOLE-3- CARBOXAMIDE (AT7519), A NOVEL CYCLIN DEPENDENT REMARK 900 KINASE INHIBITOR USING FRAGMENT-BASED X-RAY CRYSTALLOGRAPHY AND REMARK 900 STRUCTURE BASED DRUG DESIGN. REMARK 900 RELATED ID: 1OL1 RELATED DB: PDB REMARK 900 CYCLIN A BINDING GROOVE INHIBITOR H-CIT- CIT-LEU-ILE-(P-F-PHE)-NH2 REMARK 900 RELATED ID: 2WFY RELATED DB: PDB REMARK 900 TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2, CYCLIN A REMARK 900 THROUGH STRUCTURE GUIDED DESIGN REMARK 900 RELATED ID: 2UZB RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE REMARK 900 INHIBITOR REMARK 900 RELATED ID: 1H01 RELATED DB: PDB REMARK 900 CDK2 IN COMPLEX WITH A DISUBSTITUTED 2, 4 -BIS ANILINO PYRIMIDINE REMARK 900 CDK4 INHIBITOR REMARK 900 RELATED ID: 1OIR RELATED DB: PDB REMARK 900 IMIDAZOPYRIDINES: A POTENT AND SELECTIVE CLASS OF CYCLIN-DEPENDENT REMARK 900 KINASE INHIBITORS IDENTIFIED THROUGH STRUCTURE-BASED HYBRIDISATION REMARK 900 RELATED ID: 1OI9 RELATED DB: PDB REMARK 900 STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/ CYCLIN A COMPLEXED WITH A 6- REMARK 900 CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR REMARK 900 RELATED ID: 2VTJ RELATED DB: PDB REMARK 900 IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(2,6 -DICHLOROBENZOYLAMINO)- REMARK 900 1H-PYRAZOLE-3- CARBOXAMIDE (AT7519), A NOVEL CYCLIN DEPENDENT REMARK 900 KINASE INHIBITOR USING FRAGMENT-BASED X-RAY CRYSTALLOGRAPHY AND REMARK 900 STRUCTURE BASED DRUG DESIGN. REMARK 900 RELATED ID: 2CJM RELATED DB: PDB REMARK 900 MECHANISM OF CDK INHIBITION BY ACTIVE SITE PHOSPHORYLATION: CDK2 REMARK 900 Y15P T160P IN COMPLEX WITH CYCLIN A STRUCTURE REMARK 900 RELATED ID: 2C5X RELATED DB: PDB REMARK 900 DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 REMARK 900 PROVIDES INSIGHTS FOR DRUG DESIGN REMARK 900 RELATED ID: 2WEV RELATED DB: PDB REMARK 900 TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2, CYCLIN A REMARK 900 THROUGH STRUCTURE GUIDED DESIGN REMARK 900 RELATED ID: 2C5N RELATED DB: PDB REMARK 900 DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 REMARK 900 PROVIDES INSIGHTS FOR DRUG DESIGN REMARK 900 RELATED ID: 2C6M RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE REMARK 900 TRIAZOLOPYRIMIDINE INHIBITOR REMARK 900 RELATED ID: 1OIT RELATED DB: PDB REMARK 900 IMIDAZOPYRIDINES: A POTENT AND SELECTIVE CLASS OF CYCLIN-DEPENDENT REMARK 900 KINASE INHIBITORS IDENTIFIED THROUGH STRUCTURE-BASED HYBRIDISATION REMARK 900 RELATED ID: 1GY3 RELATED DB: PDB REMARK 900 PCDK2/CYCLIN A IN COMPLEX WITH MGADP, NITRATE AND PEPTIDE SUBSTRATE REMARK 900 RELATED ID: 2V22 RELATED DB: PDB REMARK 900 REPLACE: A STRATEGY FOR ITERATIVE DESIGN OF CYCLIN BINDING GROOVE REMARK 900 INHIBITORS REMARK 900 RELATED ID: 1GII RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE CDK4INHIBITOR REMARK 900 RELATED ID: 2VV9 RELATED DB: PDB REMARK 900 CDK2 IN COMPLEX WITH AN IMIDAZOLE PIPERAZINE REMARK 900 RELATED ID: 1DI8 RELATED DB: PDB REMARK 900 THE STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 (CDK2) IN COMPLEX WITH 4- REMARK 900 [3- HYDROXYANILINO]-6,7-DIMETHOXYQUINAZOLINE REMARK 900 RELATED ID: 1E9H RELATED DB: PDB REMARK 900 THR 160 PHOSPHORYLATED CDK2 - HUMAN CYCLIN A3 COMPLEX WITH THE REMARK 900 INHIBITOR INDIRUBIN-5- SULPHONATE BOUND REMARK 900 RELATED ID: 1DM2 RELATED DB: PDB REMARK 900 HUMAN CYCLIN-DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR REMARK 900 HYMENIALDISINE REMARK 900 RELATED ID: 2VTO RELATED DB: PDB REMARK 900 IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(2,6 -DICHLOROBENZOYLAMINO)- REMARK 900 1H-PYRAZOLE-3- CARBOXAMIDE (AT7519), A NOVEL CYCLIN DEPENDENT REMARK 900 KINASE INHIBITOR USING FRAGMENT-BASED X-RAY CRYSTALLOGRAPHY AND REMARK 900 STRUCTURE BASED DRUG DESIGN. REMARK 900 RELATED ID: 2UZO RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE REMARK 900 INHIBITOR REMARK 900 RELATED ID: 1H24 RELATED DB: PDB REMARK 900 CDK2/CYCLINA IN COMPLEX WITH A 9 RESIDUE RECRUITMENT PEPTIDE FROM REMARK 900 E2F REMARK 900 RELATED ID: 1H00 RELATED DB: PDB REMARK 900 CDK2 IN COMPLEX WITH A DISUBSTITUTED 4, 6 -BIS ANILINO PYRIMIDINE REMARK 900 CDK4 INHIBITOR REMARK 900 RELATED ID: 2EXM RELATED DB: PDB REMARK 900 HUMAN CDK2 IN COMPLEX WITH ISOPENTENYLADENINE REMARK 900 RELATED ID: 2CLX RELATED DB: PDB REMARK 900 4-ARYLAZO-3,5-DIAMINO-1H-PYRAZOLE CDK INHIBITORS: SAR STUDY, REMARK 900 CRYSTAL STRUCTURE IN COMPLEX WITH CDK2, SELECTIVITY, AND CELLULAR REMARK 900 EFFECTS REMARK 900 RELATED ID: 1PXP RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THEINHIBITOR N-[4-(2, REMARK 900 4-DIMETHYL- THIAZOL-5-YL)-PYRIMIDIN-2-YL]-N',N'- DIMETHYL-BENZENE-1, REMARK 900 4-DIAMINE REMARK 900 RELATED ID: 2CCH RELATED DB: PDB REMARK 900 THE CRYSTAL STRUCTURE OF CDK2 CYCLIN A IN COMPLEX WITH A SUBSTRATE REMARK 900 PEPTIDE DERIVED FROM CDC MODIFIED WITH A GAMMA-LINKED ATP ANALOGUE REMARK 900 RELATED ID: 2BTR RELATED DB: PDB REMARK 900 STRUCTURE OF CDK2 COMPLEXED WITH PNU-198873 REMARK 900 RELATED ID: 1B39 RELATED DB: PDB REMARK 900 HUMAN CYCLIN-DEPENDENT KINASE 2 PHOSPHORYLATED ON THR 160 REMARK 900 RELATED ID: 1AQ1 RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR REMARK 900 STAUROSPORINE REMARK 900 RELATED ID: 1H0W RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT PROTEIN KINASE 2 IN COMPLEX WITH THE REMARK 900 INHIBITOR 2-AMINO-6-[ CYCLOHEX-3-ENYL]METHOXYPURINE REMARK 900 RELATED ID: 1G5S RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CYCLIN DEPENDENT KINASE 2 (CDK2)IN REMARK 900 COMPLEX WITH THE INHIBITOR H717 REMARK 900 RELATED ID: 1CKP RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR REMARK 900 PURVALANOL B REMARK 900 RELATED ID: 1H28 RELATED DB: PDB REMARK 900 CDK2/CYCLINA IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM REMARK 900 P107 REMARK 900 RELATED ID: 1KE8 RELATED DB: PDB REMARK 900 CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH 4-{[(2-OXO-1,2- REMARK 900 DIHYDRO-3H-INDOL-3 -YLIDENE)METHYL]AMINO}-N-(1,3-THIAZOL-2- YL) REMARK 900 BENZENESULFONAMIDE REMARK 900 RELATED ID: 1PXL RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THEINHIBITOR [4-(2,4- REMARK 900 DIMETHYL-THIAZOL- 5-YL)-PYRIMIDIN-2-YL]-(4-TRIFLUOROMETHYL- PHENYL)- REMARK 900 AMINE REMARK 900 RELATED ID: 1H26 RELATED DB: PDB REMARK 900 CDK2/CYCLINA IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM REMARK 900 P53 REMARK 900 RELATED ID: 2VTR RELATED DB: PDB REMARK 900 IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(2,6 -DICHLOROBENZOYLAMINO)- REMARK 900 1H-PYRAZOLE-3- CARBOXAMIDE (AT7519), A NOVEL CYCLIN DEPENDENT REMARK 900 KINASE INHIBITOR USING FRAGMENT-BASED X-RAY CRYSTALLOGRAPHY AND REMARK 900 STRUCTURE BASED DRUG DESIGN. REMARK 900 RELATED ID: 1H07 RELATED DB: PDB REMARK 900 CDK2 IN COMPLEX WITH A DISUBSTITUTED 4, 6 -BIS ANILINO PYRIMIDINE REMARK 900 CDK4 INHIBITOR REMARK 900 RELATED ID: 1E1X RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR NU6027 REMARK 900 RELATED ID: 1Y8Y RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A PYRAZOLO[1,5-A] REMARK 900 PYRIMIDINE INHIBITOR DBREF 2WIH A 1 298 UNP P24941 CDK2_HUMAN 1 298 DBREF 2WIH B 173 432 UNP P20248 CCNA2_HUMAN 173 432 DBREF 2WIH C 1 298 UNP P24941 CDK2_HUMAN 1 298 DBREF 2WIH D 173 432 UNP P20248 CCNA2_HUMAN 173 432 SEQADV 2WIH GLY A -4 UNP P24941 EXPRESSION TAG SEQADV 2WIH PRO A -3 UNP P24941 EXPRESSION TAG SEQADV 2WIH LEU A -2 UNP P24941 EXPRESSION TAG SEQADV 2WIH VAL A -1 UNP P24941 EXPRESSION TAG SEQADV 2WIH ASP A 0 UNP P24941 EXPRESSION TAG SEQADV 2WIH GLU A 299 UNP P24941 EXPRESSION TAG SEQADV 2WIH ARG A 300 UNP P24941 EXPRESSION TAG SEQADV 2WIH PRO A 301 UNP P24941 EXPRESSION TAG SEQADV 2WIH HIS A 302 UNP P24941 EXPRESSION TAG SEQADV 2WIH ARG A 303 UNP P24941 EXPRESSION TAG SEQADV 2WIH ASP A 304 UNP P24941 EXPRESSION TAG SEQADV 2WIH GLY B 168 UNP P20248 EXPRESSION TAG SEQADV 2WIH PRO B 169 UNP P20248 EXPRESSION TAG SEQADV 2WIH LEU B 170 UNP P20248 EXPRESSION TAG SEQADV 2WIH GLY B 171 UNP P20248 EXPRESSION TAG SEQADV 2WIH SER B 172 UNP P20248 EXPRESSION TAG SEQADV 2WIH GLY C -4 UNP P24941 EXPRESSION TAG SEQADV 2WIH PRO C -3 UNP P24941 EXPRESSION TAG SEQADV 2WIH LEU C -2 UNP P24941 EXPRESSION TAG SEQADV 2WIH VAL C -1 UNP P24941 EXPRESSION TAG SEQADV 2WIH ASP C 0 UNP P24941 EXPRESSION TAG SEQADV 2WIH GLU C 299 UNP P24941 EXPRESSION TAG SEQADV 2WIH ARG C 300 UNP P24941 EXPRESSION TAG SEQADV 2WIH PRO C 301 UNP P24941 EXPRESSION TAG SEQADV 2WIH HIS C 302 UNP P24941 EXPRESSION TAG SEQADV 2WIH ARG C 303 UNP P24941 EXPRESSION TAG SEQADV 2WIH ASP C 304 UNP P24941 EXPRESSION TAG SEQADV 2WIH GLY D 168 UNP P20248 EXPRESSION TAG SEQADV 2WIH PRO D 169 UNP P20248 EXPRESSION TAG SEQADV 2WIH LEU D 170 UNP P20248 EXPRESSION TAG SEQADV 2WIH GLY D 171 UNP P20248 EXPRESSION TAG SEQADV 2WIH SER D 172 UNP P20248 EXPRESSION TAG SEQRES 1 A 309 GLY PRO LEU VAL ASP MET GLU ASN PHE GLN LYS VAL GLU SEQRES 2 A 309 LYS ILE GLY GLU GLY THR TYR GLY VAL VAL TYR LYS ALA SEQRES 3 A 309 ARG ASN LYS LEU THR GLY GLU VAL VAL ALA LEU LYS LYS SEQRES 4 A 309 ILE ARG LEU ASP THR GLU THR GLU GLY VAL PRO SER THR SEQRES 5 A 309 ALA ILE ARG GLU ILE SER LEU LEU LYS GLU LEU ASN HIS SEQRES 6 A 309 PRO ASN ILE VAL LYS LEU LEU ASP VAL ILE HIS THR GLU SEQRES 7 A 309 ASN LYS LEU TYR LEU VAL PHE GLU PHE LEU HIS GLN ASP SEQRES 8 A 309 LEU LYS LYS PHE MET ASP ALA SER ALA LEU THR GLY ILE SEQRES 9 A 309 PRO LEU PRO LEU ILE LYS SER TYR LEU PHE GLN LEU LEU SEQRES 10 A 309 GLN GLY LEU ALA PHE CYS HIS SER HIS ARG VAL LEU HIS SEQRES 11 A 309 ARG ASP LEU LYS PRO GLN ASN LEU LEU ILE ASN THR GLU SEQRES 12 A 309 GLY ALA ILE LYS LEU ALA ASP PHE GLY LEU ALA ARG ALA SEQRES 13 A 309 PHE GLY VAL PRO VAL ARG THR TYR THR HIS GLU VAL VAL SEQRES 14 A 309 THR LEU TRP TYR ARG ALA PRO GLU ILE LEU LEU GLY CYS SEQRES 15 A 309 LYS TYR TYR SER THR ALA VAL ASP ILE TRP SER LEU GLY SEQRES 16 A 309 CYS ILE PHE ALA GLU MET VAL THR ARG ARG ALA LEU PHE SEQRES 17 A 309 PRO GLY ASP SER GLU ILE ASP GLN LEU PHE ARG ILE PHE SEQRES 18 A 309 ARG THR LEU GLY THR PRO ASP GLU VAL VAL TRP PRO GLY SEQRES 19 A 309 VAL THR SER MET PRO ASP TYR LYS PRO SER PHE PRO LYS SEQRES 20 A 309 TRP ALA ARG GLN ASP PHE SER LYS VAL VAL PRO PRO LEU SEQRES 21 A 309 ASP GLU ASP GLY ARG SER LEU LEU SER GLN MET LEU HIS SEQRES 22 A 309 TYR ASP PRO ASN LYS ARG ILE SER ALA LYS ALA ALA LEU SEQRES 23 A 309 ALA HIS PRO PHE PHE GLN ASP VAL THR LYS PRO VAL PRO SEQRES 24 A 309 HIS LEU ARG LEU GLU ARG PRO HIS ARG ASP SEQRES 1 B 265 GLY PRO LEU GLY SER ASN GLU VAL PRO ASP TYR HIS GLU SEQRES 2 B 265 ASP ILE HIS THR TYR LEU ARG GLU MET GLU VAL LYS CYS SEQRES 3 B 265 LYS PRO LYS VAL GLY TYR MET LYS LYS GLN PRO ASP ILE SEQRES 4 B 265 THR ASN SER MET ARG ALA ILE LEU VAL ASP TRP LEU VAL SEQRES 5 B 265 GLU VAL GLY GLU GLU TYR LYS LEU GLN ASN GLU THR LEU SEQRES 6 B 265 HIS LEU ALA VAL ASN TYR ILE ASP ARG PHE LEU SER SER SEQRES 7 B 265 MET SER VAL LEU ARG GLY LYS LEU GLN LEU VAL GLY THR SEQRES 8 B 265 ALA ALA MET LEU LEU ALA SER LYS PHE GLU GLU ILE TYR SEQRES 9 B 265 PRO PRO GLU VAL ALA GLU PHE VAL TYR ILE THR ASP ASP SEQRES 10 B 265 THR TYR THR LYS LYS GLN VAL LEU ARG MET GLU HIS LEU SEQRES 11 B 265 VAL LEU LYS VAL LEU THR PHE ASP LEU ALA ALA PRO THR SEQRES 12 B 265 VAL ASN GLN PHE LEU THR GLN TYR PHE LEU HIS GLN GLN SEQRES 13 B 265 PRO ALA ASN CYS LYS VAL GLU SER LEU ALA MET PHE LEU SEQRES 14 B 265 GLY GLU LEU SER LEU ILE ASP ALA ASP PRO TYR LEU LYS SEQRES 15 B 265 TYR LEU PRO SER VAL ILE ALA GLY ALA ALA PHE HIS LEU SEQRES 16 B 265 ALA LEU TYR THR VAL THR GLY GLN SER TRP PRO GLU SER SEQRES 17 B 265 LEU ILE ARG LYS THR GLY TYR THR LEU GLU SER LEU LYS SEQRES 18 B 265 PRO CYS LEU MET ASP LEU HIS GLN THR TYR LEU LYS ALA SEQRES 19 B 265 PRO GLN HIS ALA GLN GLN SER ILE ARG GLU LYS TYR LYS SEQRES 20 B 265 ASN SER LYS TYR HIS GLY VAL SER LEU LEU ASN PRO PRO SEQRES 21 B 265 GLU THR LEU ASN LEU SEQRES 1 C 309 GLY PRO LEU VAL ASP MET GLU ASN PHE GLN LYS VAL GLU SEQRES 2 C 309 LYS ILE GLY GLU GLY THR TYR GLY VAL VAL TYR LYS ALA SEQRES 3 C 309 ARG ASN LYS LEU THR GLY GLU VAL VAL ALA LEU LYS LYS SEQRES 4 C 309 ILE ARG LEU ASP THR GLU THR GLU GLY VAL PRO SER THR SEQRES 5 C 309 ALA ILE ARG GLU ILE SER LEU LEU LYS GLU LEU ASN HIS SEQRES 6 C 309 PRO ASN ILE VAL LYS LEU LEU ASP VAL ILE HIS THR GLU SEQRES 7 C 309 ASN LYS LEU TYR LEU VAL PHE GLU PHE LEU HIS GLN ASP SEQRES 8 C 309 LEU LYS LYS PHE MET ASP ALA SER ALA LEU THR GLY ILE SEQRES 9 C 309 PRO LEU PRO LEU ILE LYS SER TYR LEU PHE GLN LEU LEU SEQRES 10 C 309 GLN GLY LEU ALA PHE CYS HIS SER HIS ARG VAL LEU HIS SEQRES 11 C 309 ARG ASP LEU LYS PRO GLN ASN LEU LEU ILE ASN THR GLU SEQRES 12 C 309 GLY ALA ILE LYS LEU ALA ASP PHE GLY LEU ALA ARG ALA SEQRES 13 C 309 PHE GLY VAL PRO VAL ARG THR TYR THR HIS GLU VAL VAL SEQRES 14 C 309 THR LEU TRP TYR ARG ALA PRO GLU ILE LEU LEU GLY CYS SEQRES 15 C 309 LYS TYR TYR SER THR ALA VAL ASP ILE TRP SER LEU GLY SEQRES 16 C 309 CYS ILE PHE ALA GLU MET VAL THR ARG ARG ALA LEU PHE SEQRES 17 C 309 PRO GLY ASP SER GLU ILE ASP GLN LEU PHE ARG ILE PHE SEQRES 18 C 309 ARG THR LEU GLY THR PRO ASP GLU VAL VAL TRP PRO GLY SEQRES 19 C 309 VAL THR SER MET PRO ASP TYR LYS PRO SER PHE PRO LYS SEQRES 20 C 309 TRP ALA ARG GLN ASP PHE SER LYS VAL VAL PRO PRO LEU SEQRES 21 C 309 ASP GLU ASP GLY ARG SER LEU LEU SER GLN MET LEU HIS SEQRES 22 C 309 TYR ASP PRO ASN LYS ARG ILE SER ALA LYS ALA ALA LEU SEQRES 23 C 309 ALA HIS PRO PHE PHE GLN ASP VAL THR LYS PRO VAL PRO SEQRES 24 C 309 HIS LEU ARG LEU GLU ARG PRO HIS ARG ASP SEQRES 1 D 265 GLY PRO LEU GLY SER ASN GLU VAL PRO ASP TYR HIS GLU SEQRES 2 D 265 ASP ILE HIS THR TYR LEU ARG GLU MET GLU VAL LYS CYS SEQRES 3 D 265 LYS PRO LYS VAL GLY TYR MET LYS LYS GLN PRO ASP ILE SEQRES 4 D 265 THR ASN SER MET ARG ALA ILE LEU VAL ASP TRP LEU VAL SEQRES 5 D 265 GLU VAL GLY GLU GLU TYR LYS LEU GLN ASN GLU THR LEU SEQRES 6 D 265 HIS LEU ALA VAL ASN TYR ILE ASP ARG PHE LEU SER SER SEQRES 7 D 265 MET SER VAL LEU ARG GLY LYS LEU GLN LEU VAL GLY THR SEQRES 8 D 265 ALA ALA MET LEU LEU ALA SER LYS PHE GLU GLU ILE TYR SEQRES 9 D 265 PRO PRO GLU VAL ALA GLU PHE VAL TYR ILE THR ASP ASP SEQRES 10 D 265 THR TYR THR LYS LYS GLN VAL LEU ARG MET GLU HIS LEU SEQRES 11 D 265 VAL LEU LYS VAL LEU THR PHE ASP LEU ALA ALA PRO THR SEQRES 12 D 265 VAL ASN GLN PHE LEU THR GLN TYR PHE LEU HIS GLN GLN SEQRES 13 D 265 PRO ALA ASN CYS LYS VAL GLU SER LEU ALA MET PHE LEU SEQRES 14 D 265 GLY GLU LEU SER LEU ILE ASP ALA ASP PRO TYR LEU LYS SEQRES 15 D 265 TYR LEU PRO SER VAL ILE ALA GLY ALA ALA PHE HIS LEU SEQRES 16 D 265 ALA LEU TYR THR VAL THR GLY GLN SER TRP PRO GLU SER SEQRES 17 D 265 LEU ILE ARG LYS THR GLY TYR THR LEU GLU SER LEU LYS SEQRES 18 D 265 PRO CYS LEU MET ASP LEU HIS GLN THR TYR LEU LYS ALA SEQRES 19 D 265 PRO GLN HIS ALA GLN GLN SER ILE ARG GLU LYS TYR LYS SEQRES 20 D 265 ASN SER LYS TYR HIS GLY VAL SER LEU LEU ASN PRO PRO SEQRES 21 D 265 GLU THR LEU ASN LEU HET P48 A1299 34 HET P48 C1299 34 HET SO4 D1433 5 HETNAM P48 N,1,4,4-TETRAMETHYL-8-{[4-(4-METHYLPIPERAZIN-1-YL) HETNAM 2 P48 PHENYL]AMINO}-4,5-DIHYDRO-1H-PYRAZOLO[4,3- HETNAM 3 P48 H]QUINAZOLINE-3-CARBOXAMIDE HETNAM SO4 SULFATE ION FORMUL 5 P48 2(C25 H32 N8 O) FORMUL 7 SO4 O4 S 2- FORMUL 8 HOH *214(H2 O) HELIX 1 1 PRO A -3 ASN A 3 1 7 HELIX 2 2 PRO A 45 LYS A 56 1 12 HELIX 3 3 LEU A 87 SER A 94 1 8 HELIX 4 4 PRO A 100 HIS A 121 1 22 HELIX 5 5 LYS A 129 GLN A 131 5 3 HELIX 6 6 THR A 165 ARG A 169 5 5 HELIX 7 7 ALA A 170 LEU A 175 1 6 HELIX 8 8 THR A 182 ARG A 199 1 18 HELIX 9 9 SER A 207 GLY A 220 1 14 HELIX 10 10 GLY A 229 MET A 233 5 5 HELIX 11 11 ASP A 256 LEU A 267 1 12 HELIX 12 12 SER A 276 LEU A 281 1 6 HELIX 13 13 ALA A 282 GLN A 287 5 6 HELIX 14 14 TYR B 178 CYS B 193 1 16 HELIX 15 15 GLY B 198 GLN B 203 5 6 HELIX 16 16 THR B 207 TYR B 225 1 19 HELIX 17 17 GLN B 228 LEU B 243 1 16 HELIX 18 18 LEU B 249 GLU B 269 1 21 HELIX 19 19 GLU B 274 ILE B 281 1 8 HELIX 20 20 THR B 287 THR B 303 1 17 HELIX 21 21 THR B 310 LEU B 320 1 11 HELIX 22 22 ASN B 326 LEU B 341 1 16 HELIX 23 23 ASP B 343 LEU B 348 1 6 HELIX 24 24 LEU B 351 GLY B 369 1 19 HELIX 25 25 PRO B 373 GLY B 381 1 9 HELIX 26 26 THR B 383 LYS B 400 1 18 HELIX 27 27 GLN B 407 TYR B 413 1 7 HELIX 28 28 LYS B 414 HIS B 419 5 6 HELIX 29 29 ASP C 0 GLU C 2 5 3 HELIX 30 30 PRO C 45 LYS C 56 1 12 HELIX 31 31 LEU C 87 ALA C 93 1 7 HELIX 32 32 PRO C 100 HIS C 121 1 22 HELIX 33 33 LYS C 129 GLN C 131 5 3 HELIX 34 34 THR C 165 ARG C 169 5 5 HELIX 35 35 ALA C 170 LEU C 175 1 6 HELIX 36 36 THR C 182 ARG C 199 1 18 HELIX 37 37 SER C 207 GLY C 220 1 14 HELIX 38 38 GLY C 229 MET C 233 5 5 HELIX 39 39 ASP C 247 VAL C 252 1 6 HELIX 40 40 ASP C 256 LEU C 267 1 12 HELIX 41 41 SER C 276 ALA C 282 1 7 HELIX 42 42 HIS C 283 GLN C 287 5 5 HELIX 43 43 TYR D 178 CYS D 193 1 16 HELIX 44 44 GLY D 198 GLN D 203 5 6 HELIX 45 45 THR D 207 TYR D 225 1 19 HELIX 46 46 GLN D 228 SER D 244 1 17 HELIX 47 47 LEU D 249 GLY D 251 5 3 HELIX 48 48 LYS D 252 GLU D 269 1 18 HELIX 49 49 GLU D 274 THR D 282 1 9 HELIX 50 50 THR D 287 LEU D 302 1 16 HELIX 51 51 THR D 310 LEU D 320 1 11 HELIX 52 52 ASN D 326 SER D 340 1 15 HELIX 53 53 ASP D 343 LEU D 348 1 6 HELIX 54 54 LEU D 351 THR D 368 1 18 HELIX 55 55 PRO D 373 GLY D 381 1 9 HELIX 56 56 LEU D 387 ALA D 401 1 15 HELIX 57 57 PRO D 402 HIS D 404 5 3 HELIX 58 58 GLN D 407 TYR D 413 1 7 HELIX 59 59 LYS D 414 HIS D 419 5 6 HELIX 60 60 GLY D 420 LEU D 424 5 5 SHEET 1 AA 5 PHE A 4 GLY A 13 0 SHEET 2 AA 5 GLY A 16 ASN A 23 -1 O GLY A 16 N GLY A 13 SHEET 3 AA 5 VAL A 29 ARG A 36 -1 O VAL A 30 N ALA A 21 SHEET 4 AA 5 LYS A 75 GLU A 81 -1 O LEU A 76 N ILE A 35 SHEET 5 AA 5 LEU A 66 HIS A 71 -1 N LEU A 67 O VAL A 79 SHEET 1 AB 3 GLN A 85 ASP A 86 0 SHEET 2 AB 3 LEU A 133 ILE A 135 -1 O ILE A 135 N GLN A 85 SHEET 3 AB 3 ILE A 141 LEU A 143 -1 O LYS A 142 N LEU A 134 SHEET 1 AC 2 VAL A 123 LEU A 124 0 SHEET 2 AC 2 ARG A 150 ALA A 151 -1 O ARG A 150 N LEU A 124 SHEET 1 CA 5 PHE C 4 GLY C 13 0 SHEET 2 CA 5 GLY C 16 ASN C 23 -1 O GLY C 16 N GLY C 13 SHEET 3 CA 5 VAL C 29 ARG C 36 -1 O VAL C 30 N ALA C 21 SHEET 4 CA 5 LYS C 75 GLU C 81 -1 O LEU C 76 N ILE C 35 SHEET 5 CA 5 LEU C 66 HIS C 71 -1 N LEU C 67 O VAL C 79 SHEET 1 CB 3 GLN C 85 ASP C 86 0 SHEET 2 CB 3 LEU C 133 ILE C 135 -1 O ILE C 135 N GLN C 85 SHEET 3 CB 3 ILE C 141 LEU C 143 -1 O LYS C 142 N LEU C 134 SHEET 1 CC 2 VAL C 123 LEU C 124 0 SHEET 2 CC 2 ARG C 150 ALA C 151 -1 O ARG C 150 N LEU C 124 CISPEP 1 ASP B 345 PRO B 346 0 -1.27 CISPEP 2 ASP D 345 PRO D 346 0 6.75 SITE 1 AC1 3 ARG D 410 LYS D 414 HOH D2079 SITE 1 AC2 12 TYR C 15 ALA C 31 LYS C 33 PHE C 80 SITE 2 AC2 12 GLU C 81 LEU C 83 HIS C 84 GLN C 85 SITE 3 AC2 12 ASP C 86 LYS C 89 LEU C 134 ASP C 145 SITE 1 AC3 10 VAL A 18 ALA A 31 LYS A 33 PHE A 80 SITE 2 AC3 10 GLU A 81 LEU A 83 HIS A 84 GLN A 85 SITE 3 AC3 10 LEU A 134 ASP A 145 CRYST1 183.000 183.000 213.560 90.00 90.00 120.00 P 62 2 2 24 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.005464 0.003155 0.000000 0.00000 SCALE2 0.000000 0.006310 0.000000 0.00000 SCALE3 0.000000 0.000000 0.004683 0.00000 TER 2428 LEU A 298 TER 4506 LEU B 432 TER 6912 LEU C 298 TER 8980 LEU D 432 HETATM 8981 O1 P48 A1299 -15.913 200.902 114.166 1.00 41.55 O HETATM 8982 C2 P48 A1299 -15.211 201.613 114.839 1.00 37.97 C HETATM 8983 N3 P48 A1299 -15.364 201.867 116.143 1.00 39.60 N HETATM 8984 C4 P48 A1299 -16.381 201.365 117.052 1.00 41.12 C HETATM 8985 C5 P48 A1299 -14.083 202.257 114.174 1.00 35.50 C HETATM 8986 N6 P48 A1299 -12.981 202.598 114.812 1.00 34.53 N HETATM 8987 N7 P48 A1299 -12.113 203.185 113.923 1.00 34.11 N HETATM 8988 C8 P48 A1299 -10.834 203.606 114.543 1.00 33.05 C HETATM 8989 C9 P48 A1299 -12.614 203.234 112.696 1.00 34.21 C HETATM 8990 C10 P48 A1299 -13.967 202.633 112.735 1.00 34.59 C HETATM 8991 C11 P48 A1299 -12.041 203.802 111.451 1.00 33.06 C HETATM 8992 C12 P48 A1299 -12.861 203.855 110.305 1.00 31.64 C HETATM 8993 C13 P48 A1299 -14.324 203.373 110.298 1.00 33.76 C HETATM 8994 C14 P48 A1299 -14.833 202.514 111.466 1.00 34.33 C HETATM 8995 C15 P48 A1299 -16.302 202.857 111.702 1.00 33.79 C HETATM 8996 C16 P48 A1299 -14.732 201.074 111.044 1.00 34.96 C HETATM 8997 N17 P48 A1299 -10.765 204.270 111.425 1.00 30.75 N HETATM 8998 C18 P48 A1299 -10.207 204.807 110.317 1.00 31.87 C HETATM 8999 N19 P48 A1299 -10.973 204.860 109.175 1.00 32.04 N HETATM 9000 C20 P48 A1299 -12.269 204.411 109.154 1.00 30.85 C HETATM 9001 N21 P48 A1299 -8.941 205.289 110.321 1.00 34.87 N HETATM 9002 C22 P48 A1299 -8.009 205.372 111.339 1.00 39.49 C HETATM 9003 C23 P48 A1299 -8.370 205.686 112.693 1.00 39.08 C HETATM 9004 C24 P48 A1299 -7.407 205.787 113.701 1.00 43.35 C HETATM 9005 C25 P48 A1299 -6.040 205.579 113.384 1.00 47.53 C HETATM 9006 C26 P48 A1299 -5.654 205.263 112.033 1.00 43.24 C HETATM 9007 C27 P48 A1299 -6.636 205.161 111.023 1.00 39.07 C HETATM 9008 N28 P48 A1299 -5.056 205.687 114.379 1.00 51.87 N HETATM 9009 C29 P48 A1299 -4.983 206.879 115.235 1.00 54.30 C HETATM 9010 C30 P48 A1299 -5.072 206.283 116.634 1.00 59.14 C HETATM 9011 N31 P48 A1299 -4.011 205.268 116.662 1.00 59.56 N HETATM 9012 C32 P48 A1299 -2.790 205.489 117.426 1.00 58.49 C HETATM 9013 C33 P48 A1299 -4.157 204.036 115.897 1.00 58.79 C HETATM 9014 C34 P48 A1299 -4.087 204.565 114.465 1.00 54.43 C HETATM 9015 O1 P48 C1299 -30.052 173.228 83.826 1.00 49.27 O HETATM 9016 C2 P48 C1299 -30.641 172.368 83.223 1.00 48.21 C HETATM 9017 N3 P48 C1299 -30.335 171.907 82.001 1.00 47.36 N HETATM 9018 C4 P48 C1299 -29.250 172.310 81.114 1.00 45.82 C HETATM 9019 C5 P48 C1299 -31.802 171.765 83.883 1.00 49.42 C HETATM 9020 N6 P48 C1299 -32.146 170.510 83.687 1.00 50.74 N HETATM 9021 N7 P48 C1299 -33.258 170.228 84.433 1.00 50.72 N HETATM 9022 C8 P48 C1299 -33.724 168.828 84.265 1.00 49.15 C HETATM 9023 C9 P48 C1299 -33.677 171.278 85.130 1.00 50.77 C HETATM 9024 C10 P48 C1299 -32.757 172.400 84.845 1.00 49.53 C HETATM 9025 C11 P48 C1299 -34.835 171.419 86.051 1.00 51.19 C HETATM 9026 C12 P48 C1299 -35.138 172.699 86.571 1.00 52.17 C HETATM 9027 C13 P48 C1299 -34.296 173.949 86.243 1.00 49.92 C HETATM 9028 C14 P48 C1299 -32.945 173.783 85.503 1.00 49.32 C HETATM 9029 C15 P48 C1299 -32.824 174.937 84.509 1.00 49.10 C HETATM 9030 C16 P48 C1299 -31.836 173.884 86.521 1.00 48.06 C HETATM 9031 N17 P48 C1299 -35.600 170.351 86.342 1.00 51.65 N HETATM 9032 C18 P48 C1299 -36.676 170.407 87.154 1.00 52.82 C HETATM 9033 N19 P48 C1299 -37.013 171.631 87.693 1.00 52.95 N HETATM 9034 C20 P48 C1299 -36.273 172.764 87.422 1.00 51.97 C HETATM 9035 N21 P48 C1299 -37.407 169.290 87.421 1.00 54.95 N HETATM 9036 C22 P48 C1299 -37.247 167.972 86.986 1.00 57.29 C HETATM 9037 C23 P48 C1299 -36.932 167.620 85.636 1.00 57.71 C HETATM 9038 C24 P48 C1299 -36.800 166.279 85.248 1.00 60.40 C HETATM 9039 C25 P48 C1299 -36.979 165.221 86.197 1.00 62.64 C HETATM 9040 C26 P48 C1299 -37.294 165.552 87.568 1.00 60.54 C HETATM 9041 C27 P48 C1299 -37.424 166.923 87.946 1.00 58.35 C HETATM 9042 N28 P48 C1299 -36.861 163.866 85.756 1.00 64.76 N HETATM 9043 C29 P48 C1299 -37.077 163.538 84.343 1.00 66.46 C HETATM 9044 C30 P48 C1299 -35.758 162.886 83.947 1.00 69.55 C HETATM 9045 N31 P48 C1299 -35.592 161.774 84.894 1.00 70.05 N HETATM 9046 C32 P48 C1299 -35.685 160.388 84.441 1.00 70.40 C HETATM 9047 C33 P48 C1299 -35.333 162.034 86.312 1.00 68.88 C HETATM 9048 C34 P48 C1299 -36.586 162.807 86.769 1.00 67.48 C HETATM 9049 S SO4 D1433 -4.595 211.349 59.474 1.00125.73 S HETATM 9050 O1 SO4 D1433 -4.828 212.738 59.920 1.00125.30 O HETATM 9051 O2 SO4 D1433 -4.940 210.415 60.562 1.00125.17 O HETATM 9052 O3 SO4 D1433 -5.435 211.064 58.296 1.00125.02 O HETATM 9053 O4 SO4 D1433 -3.173 211.177 59.115 1.00125.87 O HETATM 9054 O HOH A2001 -5.481 189.463 105.120 1.00 43.35 O HETATM 9055 O HOH A2002 -16.237 196.945 98.778 1.00 36.77 O HETATM 9056 O HOH A2003 0.373 194.465 110.002 1.00 39.81 O HETATM 9057 O HOH A2004 -1.255 195.586 113.641 1.00 41.86 O HETATM 9058 O HOH A2005 -8.310 203.482 117.126 1.00 31.50 O HETATM 9059 O HOH A2006 -9.817 201.847 119.025 1.00 48.86 O HETATM 9060 O HOH A2007 -12.334 202.038 117.847 1.00 47.05 O HETATM 9061 O HOH A2008 -3.112 204.330 102.880 1.00 45.86 O HETATM 9062 O HOH A2009 -2.377 194.716 98.569 1.00 45.91 O HETATM 9063 O HOH A2010 -1.158 195.683 101.035 1.00 41.09 O HETATM 9064 O HOH A2011 -4.699 191.290 92.430 1.00 38.08 O HETATM 9065 O HOH A2012 -3.892 200.907 97.898 1.00 45.15 O HETATM 9066 O HOH A2013 -15.552 202.609 96.538 1.00 40.37 O HETATM 9067 O HOH A2014 -13.600 204.396 99.264 1.00 44.36 O HETATM 9068 O HOH A2015 -13.505 197.239 98.488 1.00 34.22 O HETATM 9069 O HOH A2016 -8.816 204.145 98.302 1.00 42.80 O HETATM 9070 O HOH A2017 -11.656 204.328 101.669 1.00 38.83 O HETATM 9071 O HOH A2018 -15.448 221.411 104.006 1.00 37.12 O HETATM 9072 O HOH A2019 -30.534 219.876 107.474 1.00 44.63 O HETATM 9073 O HOH A2020 -22.660 205.095 104.955 1.00 33.35 O HETATM 9074 O HOH A2021 -21.745 208.551 104.287 1.00 34.79 O HETATM 9075 O HOH A2022 -21.367 211.304 100.285 1.00 49.82 O HETATM 9076 O HOH A2023 -19.692 206.318 109.880 1.00 39.28 O HETATM 9077 O HOH A2024 -18.121 210.101 103.528 1.00 37.31 O HETATM 9078 O HOH A2025 -1.783 213.683 114.278 1.00 17.16 O HETATM 9079 O HOH A2026 -6.912 207.234 119.644 1.00 44.18 O HETATM 9080 O HOH A2027 -9.561 205.658 116.909 1.00 36.86 O HETATM 9081 O HOH A2028 -7.141 214.427 123.373 1.00 38.23 O HETATM 9082 O HOH A2029 -5.848 211.967 124.910 1.00 44.70 O HETATM 9083 O HOH A2030 -5.515 230.321 115.439 1.00 44.02 O HETATM 9084 O HOH A2031 -12.067 228.268 108.507 1.00 45.07 O HETATM 9085 O HOH A2032 -11.405 231.392 111.805 1.00 47.44 O HETATM 9086 O HOH A2033 -14.832 223.569 105.711 1.00 38.79 O HETATM 9087 O HOH A2034 -8.968 216.858 108.394 1.00 25.36 O HETATM 9088 O HOH A2035 -26.159 218.591 106.085 1.00 47.70 O HETATM 9089 O HOH A2036 -18.424 221.704 104.228 1.00 41.51 O HETATM 9090 O HOH A2037 -29.810 218.877 115.335 1.00 44.98 O HETATM 9091 O HOH A2038 -29.612 217.675 106.261 1.00 47.12 O HETATM 9092 O HOH A2039 -34.285 214.966 105.006 1.00 48.54 O HETATM 9093 O HOH A2040 -18.473 206.686 124.873 1.00 37.85 O HETATM 9094 O HOH A2041 -23.468 212.222 121.557 1.00 44.45 O HETATM 9095 O HOH A2042 -12.813 210.543 123.156 1.00 12.54 O HETATM 9096 O HOH A2043 -11.766 215.560 101.886 1.00 36.15 O HETATM 9097 O HOH A2044 -10.623 221.447 107.150 1.00 34.81 O HETATM 9098 O HOH A2045 -13.971 213.023 101.669 1.00 46.78 O HETATM 9099 O HOH A2046 -23.140 205.738 118.075 1.00 28.04 O HETATM 9100 O HOH A2047 -17.333 202.057 120.569 1.00 47.54 O HETATM 9101 O HOH A2048 -26.901 201.338 118.362 1.00 45.75 O HETATM 9102 O HOH A2049 -15.752 210.818 129.791 1.00 44.66 O HETATM 9103 O HOH A2050 -20.936 217.159 129.391 1.00 31.53 O HETATM 9104 O HOH A2051 -11.474 212.376 125.196 1.00 39.08 O HETATM 9105 O HOH A2052 -24.739 213.943 125.277 1.00 35.67 O HETATM 9106 O HOH A2053 -32.310 215.745 124.640 1.00 32.12 O HETATM 9107 O HOH A2054 -31.815 219.648 117.599 1.00 45.46 O HETATM 9108 O HOH A2055 -35.376 214.805 118.908 1.00 35.72 O HETATM 9109 O HOH A2056 -14.721 218.814 126.205 1.00 30.44 O HETATM 9110 O HOH A2057 -10.048 214.183 123.872 1.00 47.45 O HETATM 9111 O HOH A2058 -3.738 219.559 126.023 1.00 43.81 O HETATM 9112 O HOH A2059 -12.608 223.519 127.878 1.00 43.18 O HETATM 9113 O HOH A2060 -10.712 220.863 134.954 1.00 51.65 O HETATM 9114 O HOH A2061 -8.471 217.604 129.467 1.00 37.93 O HETATM 9115 O HOH A2062 -15.379 221.647 134.368 1.00 28.54 O HETATM 9116 O HOH A2063 -16.339 218.107 128.424 1.00 32.31 O HETATM 9117 O HOH A2064 -21.222 207.600 138.898 1.00 45.77 O HETATM 9118 O HOH A2065 -13.389 221.005 136.030 1.00 26.81 O HETATM 9119 O HOH A2066 -15.614 224.429 132.383 1.00 49.10 O HETATM 9120 O HOH A2067 -26.638 217.677 146.175 1.00 44.24 O HETATM 9121 O HOH A2068 -9.773 232.425 131.905 1.00 43.23 O HETATM 9122 O HOH A2069 -12.148 225.884 129.589 1.00 35.27 O HETATM 9123 O HOH A2070 -10.724 236.708 122.368 1.00 45.15 O HETATM 9124 O HOH A2071 -13.327 234.942 125.070 1.00 48.38 O HETATM 9125 O HOH A2072 -22.812 236.461 117.259 1.00 40.64 O HETATM 9126 O HOH A2073 -20.373 238.567 124.390 1.00 42.25 O HETATM 9127 O HOH A2074 -25.548 235.836 116.767 1.00 48.21 O HETATM 9128 O HOH A2075 -27.121 233.602 116.985 1.00 48.36 O HETATM 9129 O HOH A2076 -25.889 227.228 129.086 1.00 46.45 O HETATM 9130 O HOH A2077 -33.057 221.255 120.393 1.00 38.39 O HETATM 9131 O HOH A2078 -33.727 224.722 118.640 1.00 44.66 O HETATM 9132 O HOH A2079 -30.294 220.991 119.635 1.00 43.44 O HETATM 9133 O HOH A2080 -23.130 230.801 108.251 1.00 43.81 O HETATM 9134 O HOH A2081 -11.713 231.151 109.288 1.00 37.96 O HETATM 9135 O HOH A2082 -8.456 229.767 106.651 1.00 48.11 O HETATM 9136 O HOH A2083 -10.506 226.667 101.811 1.00 42.48 O HETATM 9137 O HOH A2084 -2.832 216.937 106.130 1.00 36.72 O HETATM 9138 O HOH A2085 -3.096 221.595 112.154 1.00 31.32 O HETATM 9139 O HOH A2086 0.441 215.878 107.908 1.00 43.74 O HETATM 9140 O HOH A2087 5.522 206.569 111.563 1.00 48.28 O HETATM 9141 O HOH B2001 -33.577 224.989 112.800 1.00 55.02 O HETATM 9142 O HOH B2002 -37.771 220.162 109.282 1.00 49.79 O HETATM 9143 O HOH B2003 -31.931 206.918 102.526 1.00 41.74 O HETATM 9144 O HOH B2004 -45.442 208.762 100.758 1.00 48.94 O HETATM 9145 O HOH B2005 -51.441 181.490 99.127 1.00 33.78 O HETATM 9146 O HOH B2006 -57.263 183.435 103.597 1.00 37.27 O HETATM 9147 O HOH B2007 -52.641 183.483 117.276 1.00 50.68 O HETATM 9148 O HOH B2008 -55.758 190.907 116.940 1.00 39.60 O HETATM 9149 O HOH B2009 -47.972 193.485 121.551 1.00 45.14 O HETATM 9150 O HOH B2010 -40.113 197.492 126.149 1.00 45.15 O HETATM 9151 O HOH B2011 -38.128 202.595 114.454 1.00 45.48 O HETATM 9152 O HOH B2012 -45.373 197.397 109.623 1.00 40.38 O HETATM 9153 O HOH B2013 -49.360 200.547 117.612 1.00 47.59 O HETATM 9154 O HOH B2014 -47.010 199.430 110.424 1.00 40.54 O HETATM 9155 O HOH B2015 -36.867 194.767 101.212 1.00 47.72 O HETATM 9156 O HOH B2016 -54.827 172.987 102.563 1.00 41.95 O HETATM 9157 O HOH B2017 -37.456 202.301 111.659 1.00 35.43 O HETATM 9158 O HOH B2018 -43.937 202.311 120.169 1.00 23.81 O HETATM 9159 O HOH B2019 -48.008 211.385 105.712 1.00 35.46 O HETATM 9160 O HOH B2020 -51.133 194.433 107.314 1.00 51.18 O HETATM 9161 O HOH B2021 -57.991 192.890 112.574 1.00 45.39 O HETATM 9162 O HOH B2022 -60.007 193.803 108.742 1.00 33.61 O HETATM 9163 O HOH B2023 -53.334 188.899 107.087 1.00 44.88 O HETATM 9164 O HOH B2024 -49.664 198.268 104.936 1.00 50.43 O HETATM 9165 O HOH B2025 -51.821 204.457 99.968 1.00 24.29 O HETATM 9166 O HOH B2026 -65.913 211.529 109.995 1.00 48.61 O HETATM 9167 O HOH B2027 -65.989 216.511 112.528 1.00 48.66 O HETATM 9168 O HOH B2028 -60.588 193.107 113.744 1.00 46.14 O HETATM 9169 O HOH B2029 -57.226 191.162 114.779 1.00 43.85 O HETATM 9170 O HOH B2030 -58.101 192.010 118.028 1.00 37.05 O HETATM 9171 O HOH B2031 -71.519 210.061 111.933 1.00 49.49 O HETATM 9172 O HOH C2001 -39.155 181.816 96.535 1.00 44.43 O HETATM 9173 O HOH C2002 -7.463 180.271 79.215 1.00 51.07 O HETATM 9174 O HOH C2003 -27.920 187.761 90.561 1.00 46.90 O HETATM 9175 O HOH C2004 -36.529 183.759 85.668 1.00 40.30 O HETATM 9176 O HOH C2005 -22.692 184.765 95.266 1.00 39.08 O HETATM 9177 O HOH C2006 -48.318 170.282 83.597 1.00 40.85 O HETATM 9178 O HOH C2007 -31.085 178.015 75.119 1.00 37.85 O HETATM 9179 O HOH C2008 -27.850 176.116 64.629 1.00 43.87 O HETATM 9180 O HOH C2009 -36.646 170.494 61.846 1.00 36.24 O HETATM 9181 O HOH C2010 -35.161 175.782 64.547 1.00 45.09 O HETATM 9182 O HOH C2011 -35.371 176.559 69.312 1.00 45.60 O HETATM 9183 O HOH C2012 -41.010 166.905 66.441 1.00 46.68 O HETATM 9184 O HOH C2013 -39.164 161.169 55.114 1.00 39.25 O HETATM 9185 O HOH C2014 -44.652 175.546 54.829 1.00 38.22 O HETATM 9186 O HOH C2015 -44.614 177.627 53.381 1.00 28.63 O HETATM 9187 O HOH C2016 -47.362 186.464 62.651 1.00 46.35 O HETATM 9188 O HOH D2001 -1.097 182.831 88.897 1.00 46.20 O HETATM 9189 O HOH D2002 -12.296 211.390 68.798 1.00 33.44 O HETATM 9190 O HOH D2003 -13.939 192.195 63.367 1.00 45.48 O HETATM 9191 O HOH D2004 -38.500 207.054 76.871 1.00 48.35 O HETATM 9192 O HOH D2005 -35.202 205.370 76.964 1.00 36.21 O HETATM 9193 O HOH D2006 -27.795 203.486 79.678 1.00 50.62 O HETATM 9194 O HOH D2007 -18.040 210.629 85.492 1.00 46.48 O HETATM 9195 O HOH D2008 -10.936 211.599 89.513 1.00 22.37 O HETATM 9196 O HOH D2009 -9.741 206.178 91.608 1.00 43.44 O HETATM 9197 O HOH D2010 -8.524 214.168 82.523 1.00 22.24 O HETATM 9198 O HOH D2011 -5.374 203.868 81.684 1.00 40.67 O HETATM 9199 O HOH D2012 -4.838 203.349 74.470 1.00 34.67 O HETATM 9200 O HOH D2013 -10.056 206.252 69.554 1.00 24.63 O HETATM 9201 O HOH D2014 -4.650 205.773 70.242 1.00 33.62 O HETATM 9202 O HOH D2015 -12.315 197.050 67.852 1.00 34.98 O HETATM 9203 O HOH D2016 -4.869 196.283 66.751 1.00 42.26 O HETATM 9204 O HOH D2017 -5.081 193.504 63.711 1.00 45.58 O HETATM 9205 O HOH D2018 -2.277 190.979 64.617 1.00 35.12 O HETATM 9206 O HOH D2019 -13.566 186.756 66.261 1.00 40.60 O HETATM 9207 O HOH D2020 -6.085 192.067 60.735 1.00 37.50 O HETATM 9208 O HOH D2021 -16.361 188.634 66.056 1.00 33.64 O HETATM 9209 O HOH D2022 -19.137 194.702 64.376 1.00 42.62 O HETATM 9210 O HOH D2023 -26.074 192.729 73.182 1.00 36.56 O HETATM 9211 O HOH D2024 -22.908 201.807 74.246 1.00 39.16 O HETATM 9212 O HOH D2025 -19.539 200.876 67.320 1.00 40.80 O HETATM 9213 O HOH D2026 -17.413 205.324 92.477 1.00 41.80 O HETATM 9214 O HOH D2027 -14.831 206.204 93.701 1.00 37.54 O HETATM 9215 O HOH D2028 -11.550 205.270 97.715 1.00 40.48 O HETATM 9216 O HOH D2029 -12.971 199.175 95.056 1.00 32.77 O HETATM 9217 O HOH D2030 -4.381 199.941 84.858 1.00 40.21 O HETATM 9218 O HOH D2031 -2.118 202.049 91.032 1.00 37.86 O HETATM 9219 O HOH D2032 -2.062 198.876 83.492 1.00 39.52 O HETATM 9220 O HOH D2033 -1.271 196.217 77.839 1.00 48.18 O HETATM 9221 O HOH D2034 -14.798 185.902 68.722 1.00 42.04 O HETATM 9222 O HOH D2035 -19.081 186.479 67.402 1.00 41.24 O HETATM 9223 O HOH D2036 -16.920 184.505 67.659 1.00 47.25 O HETATM 9224 O HOH D2037 -0.867 183.814 84.275 1.00 37.98 O HETATM 9225 O HOH D2038 -2.707 182.623 86.879 1.00 36.08 O HETATM 9226 O HOH D2039 -13.334 187.870 93.414 1.00 38.67 O HETATM 9227 O HOH D2040 -14.753 184.352 87.613 1.00 41.57 O HETATM 9228 O HOH D2041 -27.394 193.253 75.495 1.00 37.45 O HETATM 9229 O HOH D2042 -21.922 194.614 66.546 1.00 28.78 O HETATM 9230 O HOH D2043 -34.840 205.361 70.625 1.00 39.48 O HETATM 9231 O HOH D2044 -13.427 210.322 71.028 1.00 31.36 O HETATM 9232 O HOH D2045 -21.168 206.160 74.452 1.00 40.59 O HETATM 9233 O HOH D2046 -13.430 209.180 78.951 1.00 28.46 O HETATM 9234 O HOH D2047 -12.113 214.797 75.216 1.00 45.83 O HETATM 9235 O HOH D2048 -11.997 211.954 77.341 1.00 44.52 O HETATM 9236 O HOH D2049 -13.861 213.005 78.726 1.00 36.22 O HETATM 9237 O HOH D2050 -23.378 206.987 77.573 1.00 44.82 O HETATM 9238 O HOH D2051 -34.360 214.589 54.818 1.00 43.77 O HETATM 9239 O HOH D2052 -38.482 211.390 56.470 1.00 49.12 O HETATM 9240 O HOH D2053 -34.971 209.386 76.326 1.00 46.96 O HETATM 9241 O HOH D2054 -37.264 219.193 65.582 1.00 41.57 O HETATM 9242 O HOH D2055 -0.906 215.370 60.560 1.00 37.63 O HETATM 9243 O HOH D2056 -1.846 214.142 62.829 1.00 36.60 O HETATM 9244 O HOH D2057 -29.610 215.695 72.852 1.00 36.81 O HETATM 9245 O HOH D2058 -21.355 221.841 67.889 1.00 39.87 O HETATM 9246 O HOH D2059 -12.668 214.211 69.051 1.00 42.23 O HETATM 9247 O HOH D2060 -14.946 214.242 71.840 1.00 41.20 O HETATM 9248 O HOH D2061 -12.959 214.012 61.577 1.00 38.28 O HETATM 9249 O HOH D2062 -12.066 217.235 61.143 1.00 36.82 O HETATM 9250 O HOH D2063 -14.054 224.179 69.888 1.00 35.16 O HETATM 9251 O HOH D2064 -10.239 210.406 67.336 1.00 30.71 O HETATM 9252 O HOH D2065 -3.752 212.890 66.191 1.00 45.44 O HETATM 9253 O HOH D2066 -10.844 208.915 70.354 1.00 36.55 O HETATM 9254 O HOH D2067 -2.588 209.501 75.696 1.00 45.97 O HETATM 9255 O HOH D2068 -7.341 200.577 65.879 1.00 29.24 O HETATM 9256 O HOH D2069 -10.065 207.594 67.098 1.00 26.19 O HETATM 9257 O HOH D2070 -7.943 204.295 54.506 1.00 36.63 O HETATM 9258 O HOH D2071 -9.307 195.286 58.253 1.00 41.51 O HETATM 9259 O HOH D2072 -9.865 193.506 60.266 1.00 38.73 O HETATM 9260 O HOH D2073 -10.966 195.685 55.750 1.00 15.16 O HETATM 9261 O HOH D2074 -14.465 195.522 62.648 1.00 36.34 O HETATM 9262 O HOH D2075 -14.411 203.613 50.444 1.00 33.35 O HETATM 9263 O HOH D2076 -12.182 211.416 61.567 1.00 35.20 O HETATM 9264 O HOH D2077 -15.100 211.113 58.716 1.00 40.59 O HETATM 9265 O HOH D2078 -15.255 213.715 52.253 1.00 45.02 O HETATM 9266 O HOH D2079 -4.426 213.449 62.598 1.00 38.07 O HETATM 9267 O HOH D2080 -2.619 215.252 58.608 1.00 34.44 O CONECT 8981 8982 CONECT 8982 8981 8983 8985 CONECT 8983 8982 8984 CONECT 8984 8983 CONECT 8985 8982 8986 8990 CONECT 8986 8985 8987 CONECT 8987 8986 8988 8989 CONECT 8988 8987 CONECT 8989 8987 8990 8991 CONECT 8990 8985 8989 8994 CONECT 8991 8989 8992 8997 CONECT 8992 8991 8993 9000 CONECT 8993 8992 8994 CONECT 8994 8990 8993 8995 8996 CONECT 8995 8994 CONECT 8996 8994 CONECT 8997 8991 8998 CONECT 8998 8997 8999 9001 CONECT 8999 8998 9000 CONECT 9000 8992 8999 CONECT 9001 8998 9002 CONECT 9002 9001 9003 9007 CONECT 9003 9002 9004 CONECT 9004 9003 9005 CONECT 9005 9004 9006 9008 CONECT 9006 9005 9007 CONECT 9007 9002 9006 CONECT 9008 9005 9009 9014 CONECT 9009 9008 9010 CONECT 9010 9009 9011 CONECT 9011 9010 9012 9013 CONECT 9012 9011 CONECT 9013 9011 9014 CONECT 9014 9008 9013 CONECT 9015 9016 CONECT 9016 9015 9017 9019 CONECT 9017 9016 9018 CONECT 9018 9017 CONECT 9019 9016 9020 9024 CONECT 9020 9019 9021 CONECT 9021 9020 9022 9023 CONECT 9022 9021 CONECT 9023 9021 9024 9025 CONECT 9024 9019 9023 9028 CONECT 9025 9023 9026 9031 CONECT 9026 9025 9027 9034 CONECT 9027 9026 9028 CONECT 9028 9024 9027 9029 9030 CONECT 9029 9028 CONECT 9030 9028 CONECT 9031 9025 9032 CONECT 9032 9031 9033 9035 CONECT 9033 9032 9034 CONECT 9034 9026 9033 CONECT 9035 9032 9036 CONECT 9036 9035 9037 9041 CONECT 9037 9036 9038 CONECT 9038 9037 9039 CONECT 9039 9038 9040 9042 CONECT 9040 9039 9041 CONECT 9041 9036 9040 CONECT 9042 9039 9043 9048 CONECT 9043 9042 9044 CONECT 9044 9043 9045 CONECT 9045 9044 9046 9047 CONECT 9046 9045 CONECT 9047 9045 9048 CONECT 9048 9042 9047 CONECT 9049 9050 9051 9052 9053 CONECT 9050 9049 CONECT 9051 9049 CONECT 9052 9049 CONECT 9053 9049 MASTER 829 0 3 60 20 0 7 6 9263 4 73 90 END